Interactions between valvular cells: implications for heart valve tissue engineering by Shapero, Kayle Sarah
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2013
Interactions between valvular cells:
implications for heart valve tissue
engineering
https://hdl.handle.net/2144/11048
Boston University
BOSTON UNIVERSITY 
COLLEGE OF ENGINEERING 
Dissertation 
INTERACTIONS BETWEEN VALVULAR CELLS: 
IMPLICATIONS FOR HEART VALVE TISSUE ENGINEERING 
by 
KAYLE SARAH SHAPERO 
B.S.E, Princeton University, 2008 
MSc, University College Dublin, 2010 
M.S., Boston University, 2012 
Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
2013 
© 2013 by 
KAYLE SARAH SHAPERO 
All rights reserved 
First Reader 
Second Reader
Approved by 
Professor of Surgery, Harvard Medical School 
ar Surgery, Boston Children' s Hospital 
Medical School 
Third Reader 
Fourth Reader 
Fifth Reader 
Michael Smith, Ph.D. 
Assistant Professor of Biomedical Engineering 
Matthew Nugent, Ph.D. 
Professor of Biomedical Engi ering, Biochemistry, and Ophthalmology 
Boston University School of Medicine 
Muhammad Zaman, Ph.D. 
Professor of Biomedical Engineering 
Acknowledgements 
This thesis would not have been made possible without the help of a tremendous 
group of friends, family, and mentors along the way. Thank you to the staff, and 
administrators at Boston University who gave me the oppmiunity to join the PhD 
program, and the freedom to explore my own research interests both on and off campus. 
Thank you to my fellow students who helped me throughout my time at BU both inside 
and outside of classroom, with both academic and moral suppmi. Thank you to the 
Vascular Biology and Cardiac Surgery program for welcoming me to the department and 
providing the support to excel in such a tremendous environment, surrounded by such 
strong faculty and administrators. 
A special thanks to my advisors Joyce Bischoff and Dr. John Mayer, for their 
willingness to take me on as a student, their constant guidance and support, and the 
endless teaching they provided through the course of my PhD. Thank you to all of the 
members of both the Bischoff, Mayer, and Melero-Martin lab, especially to my post docs, 
who put up with my constant questioning and always took the time out of their day to 
explain techniques or help me solve a problem. Thank you to Juan Melero-Martin, for 
serving as an excellent mentor, always willing to give important advice applicable within 
and outside of the lab. And a very special thanks is due to Jesper Hjminaes, for being a 
constant friend and collaborator, and helping me maintain my love and excitement for 
sc1ence. 
And a final thanks to all of my friends and family for supporting me all the way 
through grad school, I never would have made it if not for your love and support. 
lV 
INTERACTIONS BETWEEN VALVULAR CELLS: 
IMPLICATIONS FOR HEART VALVE TISSUE ENGINEERING 
KAYLE SARAH SHAPERO 
Boston University, College ofEngineeling, 2013 
Major Professor: Joyce Bischoff, Ph.D., Professor of Surgery, Harvard Medical School 
ABSTRACT 
Approximately 1 in 1000 children are born with congenital cardiovascular defects yearly 
in the US, including many abnormalities in heart valves. Tissue engineered heart valves 
(TEHV s) offer a solution for replacement or repair of affected valves. However, 
its therapeutic application is limited, and in ovine models, no TEHV has performed 
satisfactorily in vivo for longer than twenty weeks, in part due to the absence of 
supporting data for selection of the appropriate cell type(s) to be incorporated into the 
construct. This partially owes to the lack of a full understanding ofthe cells that inhabit 
the valve, which includes valve interstitial cells (VICs) and valve endothelial cells 
(VECs), and on the molecular mechanism underlying their interactions that maintain 
valve homeostasis. During embryonic valve development, the vast majority ofVICs are 
derived from VECs via endothelial to mesenchymal transformation (EMT). EMT in post-
natal valves is rare but it has been implicated in diseased valves. Yet, relatively little is 
known about VECs and VICs in post-natal valves in terms of specialized features, and 
how VECs and VICs might influence each other. This lack of knowledge has made it 
difficult to determine what type of cells should be used to create a TEHV. 
In order to achieve the optimal construction of a tissue engineered heart valve we 
v 
look to the native valve as our guide for proper valve structure and function. Examination 
of the native valve leaflets can contribute to our understanding of the proper cellular 
environment and how disruption of this environment affects the valves. Many common 
mitral valve pathologies including mitral valve prolapse are characterized by thickening 
of the valve spongiosa, the presence of activated myofibroblasts, and excessive 
remodeling of the extracellular matrix. By examining the cell-cell interactions in healthy 
native valves, and comparing this with observations from pathogenic valves, a greater 
understanding can be achieved and then applied to the field ofTEHV. 
In this thesis we explored the cell dynamics of the heart valve as related to natural 
homeostasis, disease progression, and tissue engineering. Using an in vitro co-culture 
model we revealed a novel two-way communication between mitral valve endothelial and 
interstitial cells. We propose that this communication promotes a healthy valve 
phenotype and function by inhibiting EndMT and suppressing VIC activation. We made 
a similar observation in the aortic valve, where VEC-VIC communication may prevent 
the process of an EndMT mediated osteogenesis in the context of calcific aortic valve 
disease. We have also used the VEC-VIC co-culture model to identify possible candidate 
cell sources for a tissue engineered heart valve. And finally, we show that cells that 
populated a tissue engineered pulmonary valve leaflet, created using an acellular scaffold, 
are phenotypically and functionally similar to native valve cells. These studies contribute 
to an understanding of the dynamics of the cellular interactions between VECs and VICs, 
and provide a new framework for identifying and testing the functionality of appropriate 
Vl 
cell sources for building a TEHV with the ability to grow with the child, maintain 
homeostasis, and prevent fibrosis and calcification. 
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Chapter 1: Background 
Introduction: 
Each year in the US approximately 1 in 1000 children are born with congenital 
cardiovascular defects. These defects include Tetralogy of Fallot, bicuspid aortic valve, 
or many other abnormalities which require the replacement/repair of one or more of the 
valves [1] . The current solution is for these children to undergo repair methods such as 
biventricular repair with a conduit [2], or replacement of the valve with a mechanical 
valve, or a non-living biological valve of cadaveric, bovine, or porcine origin [3]. While 
these treatments offer the ability to regain function of a heart valve, they present unique 
problems for pediatric patients. The younger patient requires that the implanted valve 
function for a much longer time period than a valve replacement in an adult. One of the 
complications of prosthetic valves is their short lifespan: within 15 years following 
implantation, approximately 50% of porcine aortic valves suffer the major prosthesis-
related complication-tissue failure [4]. Tissue failure is often a result of the chemical 
fixation that affects ECM architecture and prevents the normal remodeling process that 
maintains valve integrity. These bioprosthetic valves also display accelerated 
calcification kinetics, especially in the younger population [5 , 6]. Even implanted 
cryopreserved allografts of human origin still face the problem of collagen degeneration 
and ECM disruption [7]. 
Most importantly for the pediatric population, none of these valve options offer the 
potential for growth, and therefore quickly become inadequate for the developing child, 
necessitating multiple invasive surgeries tore-replace the valve. Children with congenital 
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heart disease often require more complicated valve implants than the stented or stentless 
valves required by many adults. Furthermore, recipients of prosthetic valves may require 
a lifetime of anticoagulant therapy, which can pose serious risks to young children [8]. In 
summary, the current options for treating valve defects are sub-optimal for the juvenile 
population, and this has prompted the investigation of Tissue Engineered Heart Valves 
(TEHV s) for children. 
The Solution: 
The advantage of a TEHV is that by virtue of being composed of living cells, it 
should allow for growth (via cellular proliferation, increased matrix production, cell 
hypertrophy) that is necessary for pediatric patients. The current approach used in the 
Mayer lab (since the early 2000s) [8-10], is to seed a biodegradable scaffold in vitro with 
autologous bone marrow-derived MSCs, expose the construct to flow conditions in a 
bioreactor (both static and pulsatile flow preconditioning have been evaluated) [11, 12], 
and to implant the construct in vivo into the site ofthe pulmonary valve [13, 14]. Despite 
sophisticated biomaterials and bioreactor conditioning to mimic the dynamic physical 
environment faced by the endogenous valve, the TEHV constructs have not functioned 
adequately in vivo long term, in part due to tissue contraction in the TEHV constructs. 
Contraction, along with abundant aSMA positive cells and failure to develop the 
characteristic ECM layers (fibrosa, spongiosa, and ventricularis), suggests that the 
cellular environment may not have been optimal. 
In order to achieve the optimal construction of a tissue engineered heart valve we 
look to the native valve as our guide for proper valve structure and function. Examination 
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of the native valve leaflets can contribute to our understanding of the proper cellular 
environment and how disruption of this environment affects the valves. Many common 
mitral valve pathologies including mitral valve prolapse are characterized by thickening 
of the valve spongiosa, the presence of activated myofibroblasts, and excessive 
remodeling of the extracellular matrix. These deviations from normal valve morphology 
have been challenging to treat partially due to the lack of full understanding of the 
valvular cells (interstitial cells (VICs) and valve endothelial cells (VECs)), and if and 
how the two cells interact to maintain valve structure and function. By examining the 
cell-cell interactions in healthy native valves, and comparing this with observations from 
pathogenic valves, a greater understanding can be achieved. 
Valve Structure: 
Before studying the valve cells and their interactions, one must first examine the 
environment in which they reside by delving into the valve structure. There are four main 
valves in the heart: two semilunar valves and two atrioventricular (AV) valves. The 
semilunar valves are located at the base of the pulmonary artery and the aorta, and 
separate the arteries from the ventricle. These valves are more similar to the valves in the 
veins than to the A V valves. The A V valves are smaller valves that prevent backflow 
from the ventricles into the atrium during systole, and they are attached to the ventricle 
wall via the papillary muscle via the chordae tendineae, which prevents inversion of the 
valves. In the context of this study we will focus on the mitral, pulmonary and aortic 
valves. 
The three main components of the valve are the cell types that inhabit the valve: valve 
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endothelial cells, the valve interstitial cells, and the extracellular matrix (ECM). The 
VECs form the endothelial lining on both the atrial and ventricular side of the valve while 
the VICs comprise the mesenchymal cells inhabiting the interstitium of the valve. These 
two cells types form the major functional groups of the valve, but the ECM also plays an 
important role beyond simply providing structure for the valve. The ECM, which is 
comprised predominantly of collagen, elastin and glycosaminoglycans, can influence cell 
behavior by sequestering growth factors and cytokines, transducing hemodynamic forces, 
and resisting cell traction forces. In the aortic and pulmonary valves there are three main 
layers; the fibrosa, rich in collagen which provides strength and resilience to the valve, 
the spongiosa which is comprised primarily of glycosarninoglycans and proteoglycans 
which impart compressibility to the valve, and the ventricularis layer, which is rich in 
elastin. In the A V valve these same layers also exist, but it is the atrialis layer that faces 
the flow ofblood and contains elastin instead ofthe ventricularis. [15]. These three layers 
have distinct component protein ratios [16] [17], mechanical properties, directionality 
[18, 19], and regional differences that contribute to their function and the overall 
mechanical integrity of the valve [20]. The importance ofthese valve structural proteins 
such as collagen or fibrillin is most apparent by the severe valve malformations and 
mutations that occur in their absence in animal models [22, 23]. 
Valve Development: 
The structure and cellular components of the heart valve arise through a complex 
process of heart valve development. The tissues that give rise to the heart (the mesoderm) 
first become apparent during the third week of development (in humans) during the 
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process of gastrulation. Through the sequential process of gastrulation and migration the 
endothelial plexus forms the primary endocardial tube, which is separated from the 
sunolmding layer of myocardial cells by an extracellular matrix known as the cardiac 
jelly [21]. The heart tube undergoes rightward looping and in the atrioventricular (AV) 
canal the cardiac jelly forms the cardiac cushions. The cardiac cushions eventually form 
the cardiac septa and heart valves [22, 23]. The endothelial cells lining the cushions 
undergo a process of endothelial to mesenchymal transformation (EndMT), similar to the 
process of epithelial to mesenchymal transformation in cancer development and 
metastasis [24]. During this process the endothelial cells lose their cell-cell junctions and 
invade the underlying tissue of the cardiac cushions to form the valves. [25]. This has 
been confirmed with lineage tracing experiments using a Tie2-cre reporter, in which 
interstitial cells in the pulmonary and amiic valve were shown to arise from endothelial 
cells in the cardiac cushion [26] 
Figure 1.1 The process ofEndMT in the heart to form the heart valves from the cardiac cushions [27] 
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The process of EndMT in the heart is modulated by a number of mediators, but 
for the purpose of our studies we are focusing on two subfamilies of the TGFP 
superfamily: Bone morphogenic proteins (BMPs) and TGFP families . BMP2, 4, 5, 6 and 
7 and TGF~ 1, 2 and 3 are critical to the process of EndMT in the developing heart, as 
knockout mice deficient in these components of the TGF~ signaling family have 
abnormal valve development [28-30]. BMPs and TGF~s signal through a similar 
mechanism: a complex between a type I and type II serine/threonine kinase receptor. For 
the BMPs this complex is comprised of Alk2/3 and BMPR2 [31 , 32], whereas for TGF~ 
the complex is made up of Alk1/5 and TGF~R2 receptors. Binding of the TGF~ 
superfamily components to these receptor complexes activates the SMAD transcription 
factors which then influence gene expression. BMPs phosphorylate SMAD 1/5/8 while 
the TGF~ ligands activate SMAD 2/3. These phosphorylated SMADs then 
heterodimerize with the common SMAD4 and translocate to the nucleus to activate 
transcription. The inhibitory SMADs, SMAD6/7 limit TGF~ superfamily signaling and 
their overexpression can directly inhibit EndMT [33]. The SMAD2/3 signaling cascades 
induce upregulation of certain transcription factors including Snai1-1(snail), Snai1-2 
(slug), SIPI and Twist [34, 35]. Snail and slug are the two key EMT inducing 
transcription factors and are required for valvular EndMT [36]. Studies using chick 
endocardial cushion cells indicate that Twist plays a role in EndMT by promoting cell 
proliferation, migration, and differentiation in the developing valve [3 7]. EndMT causes 
the cellular change to a mesenchymal phenotype characterized by downregulation of E-
cadherin, VE-cadherin, zona occludens 1, increased migratory capacity, and upregulation 
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ofaSMA. 
Once the process of EndMT has occurred, the VICs continue through a phase of 
remodeling and maturation of the valve interstitium to create a fully formed leaflet. 
Second and third trimester fetal heart valves contain activated VICs (expressing aSMA, 
myosin, and MMP collagenase activity) and activated VECs that express ICAM and V-
CAM. At birth the circulation alteration from fetal to neonatal also results in an increase 
in aSMA expression in the VICs. Over time the VIC density, proliferation, and activity is 
reduced as the valve matures and collagen fibers become more aligned [38, 39]. 
Valve Endothelial Cells: Phenotype and Function: 
The first major attempts to study valve development and EndMT in the 1970s also 
represent the first attempts to study the dynamic populations of cells present in the valve. 
Markwald et al. used endocardial cushion explants to make the first observations of valve 
endothelial cells undergoing EndMT and their integral role in valve development [22, 
25]. The valve endothelial cells also play an important role in the adult valve by 
maintaining hemodynamic integrity, protecting the valve from inflammatory processes 
and shear stress, and helping regulate the mechanical properties of the valve and its 
response to chemical mediators [ 40]. 
The valve endothelial cells are quite unique as compared to endothelial cells from 
other origins. From a localization standpoint, the VECs on the aortic valve tend to be 
oriented perpendicular to the flow of blood, whereas vascular endothelial cells in the 
blood vessels are oriented in the direction of flow [ 41]. From a gene expression 
standpoint, the valve endothelial cells have distinct phenotypes from many other 
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endothelial cells, for example, porcine aortic VECs have much different gene expression 
profiles when exposed to shear stress as compared to porcine aortic endothelial cells, 
particularly that the VECs expressed fewer inflammatory genes and more 
chondrogenically related genes than the aortic cells. [ 42] 
Valve Endothelial Cells: Regulation via chemical and mechanical forces: 
The valve endothelial cells are sensitive to mechanical and chemical stress, and 
may respond differently as compared to other endothelial cells. Aortic valve endothelial 
cells will align perpendicular to laminar steady flow of 20dynes/min whereas vascular 
endothelial cells will align parallel to flow [ 4 3]. VECs may change their phenotype in 
response to alterations in mechanical stimuli. When VECs are subject to cyclic strain 
they become activated: equibiaxial cyclic strain at 5% or 20% results in expression of the 
inflammatory cell adhesion molecules V-CAMl, I-CAMl, and E-selectin. Additionally, 
strain at low and high levels (20%) can lead to EndMT in VECs, albeit via different 
mechanisms- at low strain via TGF~ signaling, and at high strain via the Wnt/~catenin 
pathway [44]. An in vivo correlation ofthese observations is the fused bicuspid aortic 
valve, which represents a natural model of disrupted hemodynamic shear force. In this 
example, endothelial cells become activated and express cell adhesion molecules 
preferentially on the fibrosa side, which is more highly exposed to abnormal shear stress 
[45]. These side specific responses to shear stress, and the potential side specific 
variations in phenotype [ 46] may help explain side specific propensities for certain 
diseases, such as calcification. 
Valve endothelial cells can also respond to chemical cues. The growth factors 
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bFGF and VEGF promote mitral VEC proliferation and migration [47] , and have been 
used in our own lab to maintain an endothelial phenotype. Similar to other endothelial 
cells, VECs can be activated in response to TNFa, which increases expression of the 
leukocyte adhesion molecules E-selectin, I-CAM, and V-CAM [48] . As our lab and 
others have demonstrated, clonal populations of VECs (human pulmonary and aortic, 
and ovine mitral, aortic, and pulmonary) have been shown to undergo the process of 
TGF~ mediated endothelial to mesenchymal (EndMT) transition in vitro [48-52]. This 
ability to undergo EndMT is rather unique, as other endothelial cells may only rarely 
undergo such a process, or undergo weak EndMT [53-55]. Additionally, these studies of 
EndMT in non-valve ECs may lack the thorough documentation of the purity of the EC 
cultures. Purity of the EC cultures is important in these studies, as any mesenchymal 
contamination could be interpreted as EndMT. Work from our own group has shown for 
the first time that ovine mitral VECs harbor multilineage differentiation potential, with 
the ability to transform into VICs with osteogenic and chondrogenic capabilities [52]. 
Valve Interstitial Cells: Phenotype and Function: 
The second cellular component of the valve is the VICs, which constitute 30% by 
volumetric density of the AV valves in mice [56], and play a major role in the 
maintenance and remodeling of the extracellular matrix ofthe valve. As previously 
described, the majority of VICs are derived from VEC lining the embryonic endocardial 
cushion [57]. In the process of fetal development the VICs have an activated phenotype, 
and the VIC density, proliferation and apoptosis is much higher than in adult valves. 
After birth these valve cells become more quiescent and the collagen content of the 
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valves matures [38]. 
It has been well established that endothelial cells from the A V canal 
transdifferentiate into the mesenchymal cells within the valve during development, but 
there have been reports of additional cells contributing to the interstitium in adult valves. 
Recent lineage tracing experiments have traced a large number of cells in the adult valve 
to a hematopoietic origin. For example, in recent experiments using green fluorescent 
protein expressing hematopoietic stem cells implanted into lethally irradiated congenic 
mice, green fluorescent protein-expressing cells found within the heart valves 
demonstrated at least some synthetic functions characteristic ofVICs [58]. There is 
further evidence that bone marrow progenitor cells contribute to the valve interstitial cells 
from a study of heart valves from gender mismatched bone marrow transplant patients 
where chimeric cells in the valve were observed to express a smooth muscle marker [59]. 
Regardless of where these cells originated, once they reach the interstitium they 
contribute to the heterogeneous population ofVICS in the valve. When flrst described, 
VICs were thought to share characteristics of both fibroblasts and smooth muscle cells, 
with long processes interconnecting cells by communication junctions, and contractile 
ability upon stimulation [56]. Some reports referred to them as myoflbroblasts, due to 
their combinatory nature of matrix secretion and contractile ability [60] . For years there 
were discrepancies between descriptions of these cells, with varying reports as to the true 
nature of these VICs. A review of valve interstitial cell biology in 1996 concluded that it 
was unclear whether there existed a single myoflbroblastic VIC population, or multiple 
populations existed within the valve [61]. This heterogeneity has been observed not only 
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in VICs from a single valve [62], but also across different valves [63] . Over time, the 
VICs were delineated into several different subtypes, these include embryonic progenitor 
endothelial/ mesenchymal cells, quiescent VICs (qVICs), activated VICs (aVICs), 
progenitor VICs (pVICs), and osteoblastic VICs (obVICs) [64]. 
While the method of defming these different subsets of VICs is a constant topic of 
debate, a universal acknowledgement is that these cells play an important role in cell-cell 
communication, matrix secretion, valve remodeling and wound repair [65]. VICs express 
a variety of markers including fibroblast surface antigen, aSMA[66, 67], vimentin, 
CD44, CD105 (weakly), a1 , a3 , a5 and ~1 integrin [68] , calponin [69], and desmin [65]. 
VICs also have contractile activity [60, 65] and harbor osteogenic, adipogenic, 
chondrogenic, and myofibrogenic differentiation potential [70] . 
A challenge in working with VICs is that they will rapidly alter their phenotype in 
culture. In a healthy valve, VICs are mostly in GO arrest, maintaining a slow rate of 
turnover, and displaying a quiescent fibroblast like phenotype, expressing vimentin with 
very little aSMA (myofibroblast marker) [38, 64, 71]. This quiescent phenotype may be 
altered by certain disease states, which are characterized by an upregulation of aSMA 
positive cells [72]. In vitro culturing also adapts the phenotype of VIC from a quiescent, 
aSMA negative phenotype, to an activated phenotype with the properties of fibroblasts 
and smooth muscle cells: expressing aSMA, myosin and pro-collagen I, a contractile 
phenotype, and secreting higher levels ofECM and cytokines [67, 73]. 
Valve Interstitial Cells: Regulation via chemical and mechanical forces: 
Similarly to smooth muscle cells and myofibroblasts, VICs are affected by many 
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soluble mediators. These mediators have the ability to cause VIC activation and 
contraction, as has been demonstrated with agents including endothelin-1 [74] , 
noradrenaline, adrenaline, the thromboxane (TX) A2 mimetic U46619, 5-
hydroxytryptamine (5-HT), histamine, L-epinephrine, bradykinin, isoproterenol, and 
carbachol, [60, 75]. One ofthe well-studied VIC mediators is TGFp, which has been 
implicated in both development and disease [67] [76]. VICs are extremely sensitive to 
TGFP [77], which causes increased VIC activation, migration, proliferation, contraction, 
alterations in stress fiber alignment, and upregulation of production of ECM proteins, 
MMPS, and TIMPs [78] [79]. 
While many factors, including TGFP have been found to enhance the 
myofibroblast-like phenotype in the VICs, this effect may be countered by the addition of 
fibroblast growth factor (FGF-2). FGF-2 prevents the nuclear translocation of SMAD 
transcription factors, which prevents the myofibroblast phenotype characterized by 
increased aSMA expression, contraction, collagen production, and calcific nodule 
formation in explanted leaflets. [80] 
As previously mentioned, in vitro culturing adapts the phenotype of ovine valve 
interstitial cells from a quiescent, aSMA negative phenotype, to an activated 
myofibroblast like phenotype with the properties of fibroblasts and smooth muscle cells, 
expressing SMA and myosin and a contractile phenotype [67, 71 , 73 , 81], which is 
similar to the phenotype ofVICs in diseased valves. This aSMA positive phenotype has 
been observed in 50% to 78% of cells isolated from intact heart valves and cultured in 
vitro [66, 67]. This evidence has contributed to the consensus that culturing VICs on stiff 
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2D tissue culture plates increases their activation and expression of aSMA, thus 
highlighting the role that substrate stiffness plays in modulating cell phenotype. In fact, 
measurements have defmed the region of valve interstitial cell activation to be above a 
level of substrate stiffness of approximately 15kPa [82] , while a corresponding study 
identified aSMA expression on substrates with stiffness as low was 2.5kPa [83]. In fact, 
in some settings environmental stimuli (i.e. stiffness) had more of an influence on cell 
phenotype than chemical stimuli (i.e. TGF~) [77]. 
While substrate stiffness can strongly influence cell phenotype, dynamic forces 
can also alter cell behavior. Many studies have investigated the effects of shear stress and 
pressure both in vivo and on cells. In vivo, fused bicuspid aortic valves offer a study of 
irregular hemodynamic sheer forces that lead to increases in BMP-4, TGF~l , catabolic 
enzyme secretions and activity and bone matrix synthesis [45] . The observations have 
been recapitulated in VICs in vitro when increases in shear stress leads to immediate 
early gene responses [84] , upregulation of aSMA, [85], differentiation into 
myofibroblasts [86] , contraction [67], and calcification[87]. 
In addition to shear stress and pressure, cyclic pressure also causes drastic 
phenotypic changes in explanted valves and isolated VICs. Porcine aortic valves that 
were exposed to circumferential stretch ex vivo had upregulated collagen content and 
increases in contractility [88]. Similarly, VICs exposed to cyclic stretch undergo 
fibroblast differentiation [79] , increase their collagen secretion [89], and alter their GAG 
secretion profiles [90]. 
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Valve Cell-Cell Interactions: 
There is evidence that "dynamism and crosstalk" occur between many 
combinations of smooth muscle cells-endothelial cells in many regions of the body. It has 
been shown in vitro that endothelial cells affect smooth muscle cell proliferation [91], 
and gene expression of endothelial cells is also altered when ECs are exposed to soluble 
factors secreted from smooth-muscle cells. It is well known that proper interaction 
between vascular endothelial and smooth-muscle cells is paramount to normal vessel 
function. Vascular endothelial communication with underlying smooth-muscle cells is 
critical for the maintenance of vessel tone and inhibition of pathological smooth-muscle 
cell de-differentiation. 
The concept of vascular endothelial cells interacting with smooth muscle cells can 
also be applied to the valvular cells. It is well known that valve cells are sensitive to 
changes in their chemical and mechanical environment. We also know that VECs 
communicate effectively with one another via surface receptors and possess the ability to 
regulate one another's phenotypes in vitro [40, 92]. We, and others, have therefore 
hypothesized that VICs and VECs may be able to communicate and influence one 
another through chemical or mechanical means, and that this regulation contributes to the 
maintenance of homeostasis in the healthy valve. 
The concept of cell-cell communication in the valve has been approached from 
the in-vivo valvular level down to the in vitro co-culture level. In vivo evidence of side 
specific variations in NO synthase mRNA levels in VECs suggests that the VECs have 
the ability to transfer the effects of varying sheer stress to the VICs [46, 93]. This 
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speculation of mechanotransduction has been further investigated with a shear stress 
model of the bicuspid aortic valve. In this model, wall shear stress is sensed primarily by 
the endothelial interstitial cells, but many of the downstream effects occur in the 
interstitial cells (ECM remodeling, osteogenesis), indicating an ability of these VECs to 
transduce the signals into the tissue to alter VIC phenotype [ 45]. This has been confirmed 
with ex vivo models where shear stress induces changes in ECM remodeling [94], 
contractility [40], as well as differences in ECM deposition between intact and denuded 
valves subject to shear stress [95]. 
Valve cell interactions have been studied to an extent in vitro using co-culture and 
3D models. Co-culture studies have suggested that the aortic VECs have the ability to 
upregulate collagen, sulphated GAG production, and fibrillin-1 expression in the VICs. 
In more sophisticated 3D leaflet models, co-culturing with VECs inhibited calcium 
deposition and osteoblastic differentiation of VIC in osteogenic media [96]. In a 3D 
dynamic leaflet model incorporating shear stress, the VECs induced a more quiescent 
phenotype in the VICs (decrease in proliferation, reduction in aSMA expression) [85]. 
While these co-culturing models of tissue engineering provide insight into 
potential cell-cell communication in the valve, they often only consider the effect on a 
single cell type, and in some instances the lack of single-cell controls makes it difficult to 
determine the effect of co-culture [97]. Therefore, the field would benefit from additional 
studies to clarify and learn from the true nature of this communication to improve the 
current design of tissue engineered heart valves. 
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Valvular Disease: 
Examining valve disease that occurs through injury or age related degeneration 
serves as an example of the disruption of the normal homeostasis and cell-cell 
interactions in the valves. There are several main types of heart valve pathology which 
include inadequate formation ofthe valve architecture (in congenital heart valve disease), 
damage to collagen structure (which may lead to myxomatous degeneration) [98], 
calcification, and fibrosis with neovascularization (as in rheumatic heart disease) [15]. 
These pathologies lead to end valve dysfunction either as stenosis (failure to fully open) 
or valvular insufficiency (failure to fully close). 
We have observed that many valve pathologies share similarities with processes 
in valve development. While healthy human, canine [99] , ovine, and bovine valves lack 
VIC expression of desmin, aSMA, MMP13 and Smemb, fetal valves, myxomatous 
valves, and those experiencing abnormal hemodynamic flow have been shown to 
upregulate these proteins [ 64]. This indicates that cells in diseased and fetal valves can be 
characterized as myofibroblasts in an actively remodeling state [72]. The distinction 
between fetal and diseased valves is that in diseased valves the activated VICs have 
progressed beyond a state of fetal remodeling, and display increased proliferation [100], 
contribute to excessive ECM remodeling, disordered ECM, and contraction, ultimately 
leading to stenosis and sclerosis [67, 101-103] [104]. These pathologies may be driven at 
the molecular level by the VIC upregulation of matrix metalloproteinases, cathepsins, 
interleukin1p, collagen and catabolic enzymes [105] . 
Disease states may be characterized by a disruption of the normal homeostasis 
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present in the valve, and one specific model that exemplifies this pathology is the case of 
ischemic mitral regurgitation (IMR). Ischemic mitral regurgitation is characterized by 
leaflet thickening, fibrosis and aSMA positive VICs [106]. Our collaborators at 
Massachusetts General Hospital have developed an ovine model designed to study 
specific components of IMR in isolation. Stretch was applied to mitral valve leaflets, via 
surgical procedure, to mimic the mechanical stretch imposed by IMR [106]. 
Immunostaining of control mitral valve leaflets shows a CD31-positive endothelial layer 
and aSMA-negative VICs, as expected for a healthy valve. Mitral valves "stretched" for 
two months in vivo show activated aSMA positive VICs as well as aSMA positive cells 
along the endothelium, indicating EMT. In a similar bovine model of mitral valve 
tethering, the disruption of normal valve homeostasis resulted in increased a SMA 
expression and dysregulation of valve structure and function [ 1 06]. In the same bovine 
model, left ventricular remodeling caused an increase in mitral valve leaflet area [107]. 
These two models indicate that in the setting of ischemic cardiomyopathies and the 
presence of increased leaflet strain the valves cells may undergo the process of EMT to 
compensate. In a similar manner, valves have the ability to adapt and remodel in response 
to other stimuli, such as the changes in hemodynamic pressures instigated via pulmonary-
to-aortic autograft, where early specimens exhibit remodeling and adaptation [108]. 
Tissue Engineered Heart Valves 
In many cases of end stage valvular disease the only option is valve replacement. For 
the pediatric population this option is suboptimal as the child will outgrow and outlast the 
implanted valve. TEHV s offer the promise of a valve replacement for the pediatric 
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population with the ability to grow and mature with the child. The TEHV has yet to be 
successfully implemented in the clinic due in part to the cell sources incorporated in these 
constructs. It has been difficult to identify the ideal cell source or sources for TEHV 
because little is known about the specific properties ofVECs and VICs that are required 
for a valve to function over a lifetime. The cell type that has been most widely tested in 
TEHVs is bone marrow mesenchymal stem cells (BM-MSCs) [109] in part because of 
the feasibility of isolating autologous cells, capacity for proliferation in vitro, ability to 
synthesize ECM, and potential to differentiate into 'VICs'. BM-MSCs have been used to 
successfully seed conduits for implantation [8], but it is unclear as to the fate of these 
cells over time. In addition to mesenchymal stem cells, there are several other cell 
sources which provide the desirable characteristics of ECM production and proliferation 
capacity. These include fibroblasts [110], smooth muscle cells, and amniotic 
mesenchymal stem cells (AF-MSCs). AF-MSCs are of particular interest because they 
have been successfully implemented for tissue engineering in animal models [111, 112] 
and could be harvested as autologous cells for pediatric TE applications when the defect 
is diagnosed in utero. 
Some of the recent TEHV models have opted out of seeding endothelial cells onto the 
construct prior to implantation, instead relying on in-growth of endothelial cells from the 
pulmonary artery or attachment of blood borne ECFCs. While this method may 
theoretically work, there remains a risk of thrombosis if the process of endothelialization 
does not occur at a rapid rate. An additional drawback to the method is that BM-MSCs 
may differentiate aberrantly without an endothelial layer, and further, may over-produce 
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ECM, leading to thickening, stiffness, and valve contraction. This may explain the tissue 
contraction observed in previous studies in the Mayer lab [8]. There is limited work cited 
in the literature where scaffolds have been endothelialized prior to implantation. The cells 
that have been selected are either ECFCs [10, 14], saphenous vein endothelial cells [113], 
or fetal stem cells [114]. 
Based on the previous evidence of the importance of cell-cell regulation in the valve, 
there have been some limited efforts to construct tissue engineered heart valves that more 
closely resemble the native valve leaflet by incorporating both endothelial and 
mesenchymal cell sources. Some ofthese efforts rely on the use of progenitor cells that 
can theoretically differentiate into two different cell types to repopulate the valve. A 
specific example of this is the fetal implantation of TEHV s seeded with autologous 
amniotic fluid derived stem cells [115]. This single cell approach was based off of 
evidence that bone marrow derived mesenchymal stem cells seeded onto a tissue 
engineered graft can develop into functional blood vessels complete with an smooth 
muscle and endothelial cell layer [116]. Interestingly though, this two cell system arises 
not through MSC differentiation but rather through host endothelial cell attraction and 
remodeling [116]. The choice for amniotic fluid derived stem cells in this study was in 
part due to the enhanced ability of this specific cell type to recruit host progenitor cells 
and secrete inflammatory and chemoattractive factors [117, 118]. 
Additional efforts to achieve a two-cell construct in tissue engineered heart valves 
have been attempted by seeding the matrix with two different cell sources. Examples of 
this approach include the combination of umbilical cord myofibroblasts and blood 
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ECFCs [119], ovine endothelial cells and fibroblasts [110], ovine endothelial cells and 
myofibroblasts [4, 14], and fetal chorionic villi derived MSCs and umbilical cord derived 
EPCs [120]. While these combinations of cells have been used to create a multi-layer 
construct, these constructs lack the longevity of function in vivo. In addition to 
functionality in vivo, these tissue engineered valves express activated aSMA positive 
VICs, a hallmark of certain stressed or diseased valves [119, 121], which we hypothesize 
is an indication that TEHV have not achieved a healthy cellular equilibrium. And more 
importantly, it is still unknown how these cell types may interact to regulate one another 
in the valve. While some data exists comparing alternative cell sources with native valve 
cells in terms ofECM production and other general observations [122], there is no 
evidence as to how these alternative sources might functionally interact with one another. 
This lack of knowledge, coupled with the challenges in successfully creating a tissue 
engineered heart valve, has driven the field to understand the dynamics of the heart valve 
cells. It is clear that both interstitial cells and endothelial cells play an integral role in 
maintaining the structure and integrity of the heart valve, functions that are critical to 
preserve in the TEHV. 
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Chapter 2: Materials and Methods: 
Materials: Materials used were Endothelial Basal Medium (EBM)-2 and EGM-2 Single 
Quots (CC- 3156 and CC-4176 respectively, Cambrex BioScience, Walkersville, MD), 
fetal bovine serum (FBS) (Hyclone, Logan, UT), GPS (Invitrogen, Carlsbad, California), 
TNF-a, hTGF~-1 (R&D Systems, Minneapolis, MN), bFGF (Roche Diagnostics, 
Indianapolis, IN), FITC-anti-goat IgG, Texas Red antimouse IgG, peroxidase conjugated 
anti mouse IgG, anti-goat IgG (Vector Laboratories, Burlingame, CA), FITC-conjugated 
anti-human CD31 (Ancell, Bayport, MN), mouse anti-human aSMA (Sigma Aldrich Co., 
St. Louis, MO), goat anti-human CD31, goat anti-human VE-Cadherin (Santa Cruz 
Biotechnology, Santa Cruz, CA), rabbit anti-human von Willebrand Factor (vWF), rabbit 
polyclonal anti-vimentin antibody (Abeam, Cambridge, MA), IB4-Isolectin (Vector Labs, 
Burlingame CA), SMA22alpha (Abeam, Cambridge, MA), FITC-streptavidin and Texas 
Red-streptavidin (Amersham Life Sciences, Arlington Heights, IL), RNeasy kit and 
RNase-free DNase (Qiagen, Valencia, CA), Collagenase A (Roche Diagnostics, 
Indianapolis, IN), Type I collagen (Cohesion Technologies Inc., Palo Alto, CA and BD 
Biosciences, Bedford MA), phenol red-free Matrigel (BD Biosciences, Bedford, MA). 
Immobilon-P membrane (Millipore, Bedford, MA), Hyperfilm ECL, 24mm Transwells 
with 0.4)..lm pore polycarbonate membrane inserts, 12mm Transwells with 0.4)..lm pore 
polycarbonate membrane inserts, 6.5mm Transwells with 8.0)..lm pore polycarbonate 
membrane inserts (Coming Life Sciences, Acton, MA), 
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Hydrogel materials: Methacylic anhydride (Sigma-Aldrich, St. Louis, MO), hyaluronic 
acid (Lifecore Biomedical, Chaska, MN), gelatin from porcine skin (Sigma-Aldrich, St. 
Louis, MO), Photoinitiator (Igracure 2595), Alizarin Red S (ARS) solution (Sigma, St. 
Louis, MO), Alkaline phosphatase colorimetric kit (Biovision Lifesciences, Milpitas, CA, 
USA). LIVE/DEAD Viability kit for mammalian cells (Invitrogen, Carlsbad, California) 
Cell Culture: 
Cell Isolation and Creation of Clones: Ovine tissues from animals weighing 20 to 25 kg 
and 8 to 10 months of age were obtained under approved guidelines for animal 
experimentation at Children's Hospital, Boston. Valve leaflets were incubated in EBM-2 
media with 5% FBS, 1% GPS, 2 mmol/L L-glutamine, and 100 1-lg/ml gentamicin sulfate 
for 1 to 4 hours, then minced into 2 mm pieces, incubated with 0.2% collagenase A in 
EBM-2 media for 5 minutes at 37°C, and diluted with Hanks' balanced salt solution 
containing 5% FBS, 1.26 mmol/L CaCh, 0.8 mmol/L MgS04, and 1% GPS (wash 
buffer). The supernatant was sedimented at 200 x g, resuspended in growth medium, and 
plated. The following day, primary cultures were washed to remove unattached cells and 
refed. Primary cultures were trypsinized, resuspended in growth medium at 3.3 cells/ml, 
and 100 Ill plated in each well of a 96-well plate, at a concentration of approximately one 
cell to every third well, and visual inspection was performed to assess that single colonies 
appeared in a subset of wells. When the colonies covered two-thirds of the well, cells 
were split into 24-well dishes. Clones were designated as endothelial: MVEC-4, MVEC-
5, MVEC-E10, or interstitial: MVIC-7, MVIC-B12, MVIC-G8, MVIC-K19, and 
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expanded on 1% gelatin-coated dishes in EBM-B medium (10% heat-inactivated FBS, 
1% GPS, and 2 ng/mL basic fibroblast growth factor). Cells were passaged 1:3 or 1:4 
every 6 to 14 days and used between passages 8 to 14, all grown in EBM-B media. The 
same protocol was followed for isolation of ovine aortic valve endothelial clone (W A V-
1) [123 , 124], and aortic interstitial cells clones (AVIC-K3, AVIC-K5, AVIC-K6). 
Non-Valvular Cells: Endothelial cells from ovine carotid arteries (CAECs) were isolated 
by collagenase (0.2% vol/vol final) and dispase (2.5 U/mL final) digestion for 1 hour at 
37°C. The tissue digest was passed through a 100-)..lm strainer and plated on gelatin-
coated plates in EGM-2 medium. Endothelial-like colonies were collected and plated by 
limiting dilution as described above. Clones CAEC-3 and CAEC-13 were analyzed by 
flow cytometry. Sheep endothelial progenitor cells (ECFCs) were isolated from 
peripheral blood samples as described [125]. BM-MSCs were isolated as described [123]. 
Nonvalvular ECs are not transformed cell lines, and additionally they were grown in the 
same medium and under identical conditions as the MVECs for all experiments presented 
here. For the fibrocyte isolation, peripheral blood mononuclear cells (PBMCs) were 
isolated from patients with idiopathic pulmonary fibrosis (IPF). PBMCs were isolated 
using Ficoll density centrifugation. Cells were thereafter cultured in growth medium 
EGM2, supplemented with 5% fetal bovine serum. Typically, 5x106 PBMCs were plated 
into each well of a 6-well plate. When adherent cells showing a mesenchymal phenotype 
appeared in culture, they were harvested by trypsinisation, replated and cultured in EBM 
supplemented with 20% FBS, penicillin and streptomycin. They were thereafter 
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characterized as fibrocytes using flow cytometry and RTQ-PCR (Smadja et al, submitted 
to Am J Path) 
Proliferation assay: Cells were seeded in triplicates onto 1% gelatin-coated 24-well 
plates (5x103 viable cell/cm2) using EBM-B medium. Plating efficiency was determined 
at 24 h. Cells were then treated for 48 h using fresh medium. Cells were trypsinized and 
counted using a hemocytometer. Values were normalized to cell numbers at 24 h. 
Cell Treatments: Recombinant human TGF~l, anti-TGF~l, VEGFA (Sigma), Avastin 
(were reconstituted at stock concentrations according to the manufacturer's instructions 
and stored at - 20°C until use. These were added to the culture assays at varying doses for 
specified periods of time according to the experimental condition. 
Endothelial to Mesenchymal Transition (EndMT) Assay: Cells were grown in basal 
media (EGM-2, 20% FBS, 1% PSG, and 2ng/ml bFGF) or basal media supplemented 
with 2ng/ml TGF~ 1 for five days. The growth media was replaced with fresh media every 
two to three days. Upon completion of the experiment the cells were lysed and prepared 
for Western Blot, RNA extraction, or indirect immunofluorescence. 
Co-culture/Conditioned Media Treatment: For the co-culturing experiments, cells were 
plated either in the insert or the bottom of 6 well transwell plates (Corning, Tewksbury, 
MA) at a density of lx105 cells/cm2, and allowed to adhere overnight. After 24hrs the 
24 
two cell types were placed in indirect co-culture by placing the inserts into the same well. 
Cells were then treated for the specified amount of time in basal media supplemented 
with additional growth factors depending on the experiment. For the conditioned media 
experiments, cells were treated with media that had been conditioned by the specific cell 
type for 24hrs, at which point it was sterile filtered and added in a 1:1 ratio with fresh 
media to treated cells. Media was replaced with fresh media every 2-3 days 
Cell Function Assays: 
3H Proline Assay: Cells were plated in 96 well plates at a density of 10,000 cells/well in 
normal media (EBM-B). After 24hrs, cells were treated with proline free media (DMEM) 
for 30mins, and washed 3x5mins with PBS. 1 uCi of 3H proline was added to media per 
well (DMEM + P/S/G, 50ug/ml L-ascorbic acid), and cells were incubated for desired 
amount of time. To analyze soluble collagen content, supernatant was collected and 
protein was precipitated and washed with 1 0% TCA and subsequent centrifugation at 
14,000G for 30mins. Pellet was then suspended in 0.3 ml of0.3 M NaOH/0.3% SDS and 
incubated at 37 °C for one hour until solubilized, and then the total volume was added to 
4 ml of liquid scintillant. To analyze the total insoluble cell associated collagen cells were 
washed with PBS and then trypsinized into 1 ml of ice-cold 1 0% TCA. Cells were then 
centrifuged at 14,000 g for 20 mirt to precipitate protein. The cell layer precipitate was 
then solubilised at 37 oc for 1h in 0.3 ml of 0.3M NaOH/0.3% SDS and added to 4 ml of 
liquid scintillant. Total 3H counts were detected using a Perkin Elmer Tri-Carb2900TR 
liquid scintillation analyzer. 
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Migration Assay. One hundred 11g/mL rat tail collagen type I (0.02N acetic acid) was 
used to coat 6.5mm Transwells with 8.0 11m pore polycarbonate membrane inserts for 1 
hour at 37°C followed by one wash with PBS. Cells were treated as specified, trypsinized 
and seeded in the upper chamber ofthe transwell plate at a density of 10,000 cells/well 
(lOO!lL volume). Three hundred IlL of control media (EBM-2/serum- and growth factor-
free) or EBM-B with 20% FBS was added to the lower chamber. Cells were then allowed 
to migrate for 4 hours at 37°C. The cells in the upper chamber were gently removed using 
a cotton swab and the lower surface was fixed with ice-cold methanol and mounted on to 
glass slides in mounting media containing DAPI. Cells were counted using a fluorescent 
microscope. 
Tube formation in Matrigel. Matrigel (50!lL) was added to 24-well plates and allowed 
to polymerize for 30 minutes at 37°C. Cells that were prepared using different treatments 
were suspended in EBM-B medium and added to the Matrigel plates at a concentration of 
2x104 cells/cm2) and incubated at 37°C for 24 hours after which tube formation was 
visualized using a phase contrast microscope. 
Collagen Gel Contraction Assay: Cells were plated in 6-well plates and cultured for 5 
days with specified treatment (conditioned media, TGF~, etc.). After 5 days, cells were 
trypsinized and seeded into collagen gels (3mg/ml type I Collagen, 10% DMEM, 25mM 
HEPES, titrated to pH 7.3 with 1M NaOH). Gels were prepared at a volume of0.5ml 
gel/well, and were incubated for one hr at 37°C to polymerize. Following one hr, lml of 
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EBM- B media was added to each well, and gels were released from the sides of the plate 
with a 27G needle. Surface area of free-floating gels was imaged using a camera and 
surface area was calculated using ImageJ. Gel weight was determined by fixing gels in 
4% paraformaldehyde for 24hrs and weighed on a scale to determine volumetric changes. 
Leukocyte Adhesion: For leukocyte adhesion assays, valve endothelial cell monolayers 
were grown in their necessary treatments in p35 plates. Following treatment, cells were 
challenged with or without 10 ng/ml of tumor necrosis factor-a (TNF-a) for 5 hours. 
Afterwards, the leukemia cell line HL-60 (2 x 106 cells) was added and incubated at 4 oc 
in HL-60 media (RPMI1640 media with 20%FBS and 1 %GPS) on a rocking platform for 
45 min. Cells were then washed five times with cold RPMI1640 media and fixed with 4% 
paraformaldehyde for 30 minutes. Bound leukocytes were visualized and quantified using 
a phase-contrast microscope and ImageJ analysis software. 
Acetylated LDL Uptake: The cells were grown in their specified treatment for the given 
number of days, at which point they were washed with PBS. The cells were then treated 
with 50mg/ml Dil-acetylated LDL for 4-6hrs, at which point they were washed three 
times with PBS, fixed for 20mins in ice cold methanol, and stained with DAPI. 
VIC Activation Assay: VICs were plated at a density of 1x1 05 cells/cm2 in 4-chamber 
culture slide in DMEM + 10% FBS. Cells were treated for 4 days in DMEM-10% FBS 
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plus 100 ng/mL VEGF, 5 ng/mL TGFP or 100 ug/mL Heparin. After 4 days, cells were 
fixed in 4% PF A and stained for aSMA. 
Osteogenesis: Valve cells were cultured for 2 or 3 weeks in DMEM low-glucose medium 
with 10% FBS, I x GPS, and osteogenic supplements (1 ~mol/L dexamethasone, 10 
mmol/L P-glycerophosphate, 60 ~mol/L ascorbic acid-2-phosphate ). Differentiation was 
assessed by von Kossa and alkaline phosphatase staining, osteocalcin staining, and 
detection of rnRNA transcripts encoding osteogenic markers. 
Further analysis: 
Indirect immunofluorescence. Cells were plated onto gelatin-coated coverslips or 8-well 
slides and fixed with ice-cold methanol for 20mins, then rinsed three times with PBS and 
incubated with respective primary Abs (Mouse IgG, CD31, vWF, VE-Cadherin, decorin, 
vimentin, aSMA, Isolectin B4) followed by species-specific FITC- or Texas Red-
conjugated secondary Abs, then DAPI, and then analyzed using a fluorescence 
microscope. 
RNA extraction and PCR. RNA was extracted using RNeasy Mini Kit (Qiagen, 
Valencia, CA). eDNA synthesis was performed with iScript eDNA Synthesis Kit (Bio-
Rad Laboratories, Hercules, CA). DNAse I (Invitrogen, Carlsbad, CA) digestion of RNA 
samples (0.5ug) was performed prior to reverse transcription. Primers used are listed in 
Table 1. 
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Quantitative real time PCR. RNA was extracted using an RNeasy Mini Kit (Qiagen, 
Valencia, CA). eDNA synthesis was performed with iScript eDNA Synthesis Kit (Bio-
Rad Laboratories, Hercules, CA). DNAse I (Invitrogen, Carlsbad, CA) digestion of RNA 
samples (0.5ug) was performed prior to reverse transcription. Primers used are listed in 
Table 1. All reactions were performed using Fast start SYBR Green PCR Master Mix, at 
the default setting on an ABI Biosystems StepOnePlus Real Time PCR Machine with the 
following temperature profiles: denature at 95°C for 10 minutes, and 40 cycles of95°C 
for 15sec, and 60°C for 1 min. All PCR products were sequenced using ABI DNA 
sequencer (Children's Hospital Boston core facility) to verify the sequence corresponded 
to the gene of interest. 
Western blotting. Cells were lysed with 4 mol/L urea, 0.5% SDS, 0.5% NP-40, 100 
mmol/L Tris, and 5 mmoVL EDTA, pH 7.4, containing 100 J.Lmol/L leupeptin, 10 
mmol/L benzamidine, 1 mmol/L PMSF, and 12.5 !lg/ml aprotinin. Lysates were 
subjected to 10% SDS-PAGE (13!lg ofproteinper lane) and transferred to Immobilon-P 
membranes. Membranes were incubated with respective primary Abs (goat anti-human 
CD31, goat anti-human VE-cadherin, mouse anti-human a-SMA, and mouse anti-human 
~-actin) diluted in 5% dry milk in lx PBS-T (0.1% Tween-20, 25!-LM Tris-HCl, 0.15M 
NaCl in PBS), and then with secondary Ab (peroxidase-conjugated anti-mouse or anti-
goat). Antigen-Ab complexes were visualized using chemiluminescent sensitive film. 
Equal protein amounts were loaded in each lane (determined by )l-BCA assay, Pierce), 
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and expression was quantified via densitometry analysis and normalized to that of P-actin 
(1:1000; Sigma). 
Flow cytometry. Ovine cells that had been cultured in EBM-B were removed from the 
culture plate with cell dissociation buffer, and frrst fixed for 30mins in 4% 
paraformaldehyde, followed by 10mins in 0.5% saponin in 1 %BSA/PBS. Cells were then 
washed and incubated with PE/ FITC-conjugated Abs (CD-31 or aSMA) on ice for 60 
min. Cells were then washed twice and resuspended in 1% paraformaldehyde in PBS. 
Flow cytometric analyses were performed using a Becton Dickinson F ACScan flow 
cytometer and FlowJo software. 
Mechanical characterization of collagen gels: Rheological measurements at oscillatory 
shear deformation were carried out with a rheometer using parallel rough plates of 25 mm 
diameter and plate-to-plate distance of 1 mm. Collagen gels were positioned on the 
temperature-controlled plate and the mechanical spectra were recorded in a constant 
strain mode with a low deformation of 0. 01 maintained over the frequency range of 0.1-
100Hz (rad/s) at 37°C. 
DAPI Cell Cycle Analysis Cells were removed from the culture plate with cell 
dissociation buffer, and first fixed for 30mins in 4% paraformaldehyde and then 
resuspended in a solution of 1 0~-Lg/ml 4,6-diamidino-2-phenylindole (DAPI) and 0.1% 
nonidet P-40 detergent in 1 %BSA/PBS. The suspension was analyzed using a Flow 
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cytometer, with ultraviolet excitation and DAPI emission collected at >450nm. DNA 
content and cell cycle were analyzed using the a Becton Dickinson LSR II flow 
cytometer and FlowJo software program 
Hydrogel Methods: 
Synthesis of hydrogel materials To prepare HAMA methacrylic anhydride and 1 wt% 
hyaluronic acid were combined in DI water. The pH was adjusted to 8 with 5M NaOH 
and placed on ice for 24hrs. This solution (MeHA) was dialyzed for 72 hrs, lyophilized, 
and stored at -80°C [126]. To prepare the GelMA, a 10% wt gelatin solution was created 
by heating and dissolving type A gelatin from porcine skin in PBS for 20mins at 60°C. 
8% (v/v) methacrylic anhydride was added dropwise with constant stirring over 3hrs at 
50°C. This Gelma solution was dialyzed with DI water for one week at 40°C, lyophilized 
for 96hrs, and stored at -80°C. [127] 
Formation of hydrogels: 1 mL PI solution (1mg PI in 1ml PBS) was added to 10mg HA 
and 50mg Gelma and heated at 80°C for 20mins with frequent vortexing to yield a 
1 %MeHA/5%GelMA prepolymer solution. To fabricate the hydro gels, 50!11 ofthe 
prepolymer solution was placed on a petri dish between 450~-Lm high spacers and topped 
with a glass slide to create a cylindrical gel of height 450~-Lm. Gels were then 
photocrosslinked with 360nm wavelength light for 30 seconds (450W, 2.5W/cm2) 
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Alizarin Red Staining: To visualize the deposition of calcium, cells were fixed for 
20mins in 4%PF A and stained with 0.02 mg/mL Alizarin Red S (ARS) solution to stain 
calcium deposition red. 
Alkaline Phosphatase Activity Assay: A colorimetric kit was used to measure ALP 
activity. Per manufacturer's instructions, 16ul of supernatant from 12well plates was 
added to 64J..LL of ALP assay buffer and 50 J..LL ofPnPP solution was added and incubated 
for 1 hour at room temperature. The absorbance was read at a wavelength of 405 nm. 
Values were normalized to the standard curve. 
Cell viability and apoptosis: Cell viability was determined by fluorescent labeling with 
4J..LM Calcein AM and 2J..LM Ethidium Homodimer-1 (LIVE/DEAD Viability kit for 
mammalian cells, Invitrogen). Per manufacturer's instructions, Hydrogels were washed 
with PBS and stained with fluorescent dye for 20mins. Hydrogels were then washed in 
PBS and imaged with an A1/Cl confocal microscope (Nikon Instruments, Inc. Melville, 
NY). 3 z-stacks (lOJ..Lm per slice) were taken of each hydrogel (3 hydrogels per condition) 
and viable cells were counted using Image J Software. 
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ShSnail.l-F ATCAGCTGGGCTTCTCTCCT 
ShSnail.l-R TGAAGGCTTTGCGAGACTG 
ShSlug.2-F GGACGCACACCTTACCTTGT 
ShSlug.2-R CGAGAAGGTTTTGGAGCAAC 
bosNFATc1.2-F CTGCGTGGTGTCTGTCTGTT 
bosNFATc1.2-R GAGGTCTGTCTTCCGTGCTC 
MMP-1.3-F TATCGGAGGAGACGCTCATT 
MMP-1.3-R AGTGGGATTTTGGGAAGGTC 
MMP-2.3-F GAGACTCCCACTTCGACGAC 
MMP-2.3-R AACACCAGAGGAAACCATCG 
ShBactin-3F CTCTTCCAGCCTTCCTTCCT 
ShBactin-3R GGGCAGTGATCTCTTTCTGC 
ShRPS9-2F GGAGACCCTTCGAGAAGTCC 
ShRPS9-2R GGGCATTACCTTCGAACAGA 
GAPDH-F ACCACAGTCCATGCCATCAC 
GAPDH-R TTCACCACCCTGTTGCTGTA 
BovN-Cad-2F TCCCCCTCTCATCTGAACAC 
BovN-Cad-2R GATGGGAGGGATAACCCAGT 
Sh VE-Cadherin-F ACATCCGTGGTTCTGGACTC 
Sh VE-Cadherin-R AGATGGGGAAGTTGTCGTTG 
ShSMA-F TGCCATGTATGTGGCTATTCA 
ShSMA-R ACCAGTTGTACGTCCAGAAGC 
Chondromodulin-1F CACCAGCAGGAAGGAGAAAG 
Chondromodulin-1R TTATAGGGCCATGGGTGGTA 
Osteocalcin-F AGCTCATCACAGTCAGGGTTG 
Osteocalcin-R AGCGAGGTGGTGAAGAGA 
Osteopontin-F CTGATTTTCCCACTGACATT 
Osteopontin-R CTATGGAATTCTTGGCTGAG 
Table 2.1 Primers for qRT-PCR experiments 
33 
Chapter 3: Valve Cell Characterization 
Mitral Valve VEC and VIC Clones: 
The Bischofflab has long-standing expertise in valve cell biology, and has 
optimized the technique of isolating and expanding single cell clones ofVECs and VIC 
from primary cell cultures. The rationale for using clonal populations of valvular cells 
derives from the inherent variability that exists within populations of cells. For example, 
isolating clones of VECs allows separation of VECs into clones that do not appear to 
undergo EMT and clones that do undergo EMT to varying degrees. The difficulty with 
experimenting on primary cell cultures is the possibility of differential proliferation 
and/or responses of subsets of cells, i.e., preferential growth of rare mesenchymal cells 
that might be present in a primary culture of endothelial cells. While the use of VEC and 
VIC clones does not predict the response of the entire population of cells in the valve, we 
believe it provides a cleaner system for studying the valve cells, and eliminates the issue 
of an ever-changing primary cell culture. 
Mitral Valve Endothelial Cells: 
Valve endothelial cells have been characterized by the Bischoff lab. Clonal VECs 
display a cobblestone morphology (see Figure 3.1) and express the widely-used 
endothelial cell markers CD31, (Platelet Endothelial Adhesion Molecule (PECAM -1)) 
and VE-cadherin. The mitral VECs do not express the myofibroblast/smooth muscle cell 
marker aSMA. This is confirmed by immunofluorescence and flow cytometric analyses 
Figures 3.1 and 3.2 respectively. In Figure 3 .2, all VEC clones express some level of 
CD31 but limited to no expression of aSMA. The negative staining with IgG isotype-
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matched controls is shown in the left hand column. 
MVEC-4 MVEC-5 MVEC-ElO 
Figure 3 .1 . Characterization of mitral VECs. The top row displays cell morphology from phase 
contrast images. The bottom three rows represent immunostaining of these mitral VEC clones 
with anti-CD31, anti-VE-cadherin and anti-aSMA; second, third and fourth rows respectively. 
Antibodies were conjugated with FITC such that positive staining appears as green fluorescence. 
Nuclei were stained with DAPI (blue fluorescence). The results show that mitral VEC exhibit a 
typical endothelial cobblestone morphology and express the endothelial markers CD31 and VE-
Cadherin, but express little to no 
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Figure 3.2. Six different mitral VEC clones were saponin-permeabilized and analyzed by flow 
cytometry with FITC-conjugated anti-CD31 and PE-conjugated aSMA (right column). Controls 
with isotype-matched control antibodies are shown in the left column. All clones express CD31; 
clone A3 and B8 express little to no aSMA ;c while clones AS, B6, C8, ElO some degree of 
a SMA. 
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Mitral VECs express little to no aSMA in their basal state. aSMA is induced in 
VECs undergoing EndMT and is therefore as a marker ofEndMT. In culture the process 
of EndMT is induced with TGF~ treatment. We have confirmed the ability of three 
different mitral VEC clones to undergo TGF~ 1-mediated EndMT, and have also 
identified clones that will not. The western blot data in Figure 3.3 illustrates the 
heterogeneity in response ofthe MVEC clones to TGF~ treatment [52]. It also 
demonstrates that some clones, (B8, C8) may spontaneously express aSMA, which is 
confirmed in the flow cytometry data in Figure 3.2. We have at our disposal eight 
different mitral VEC clones that have been characterized, grow easily in culture, and can 
be cryopreserved when not in use for experiments. The Bischoff lab has published five 
papers concerning the topic of VECs, and has extensive experience working with these 
cells [48-52]. TGF~ 1-mediated EMT has been implicated in EndMT during valve 
development. In disease models-MI stretch for example- we observe TGF~ expressed in 
an endothelial/subendothelial location [106] . In these disease models EndMT is occurring 
based on the presence of an enhanced CD31-positive/aSMA positive population, and 
these observations suggest the potential role of TGF~-mediated EndMT in valve disease. 
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Figure 3.3. Mitral VEC clones were treated with TGF~ for 8 days and analyzed for a-SMA as a 
marker ofEndMT in mitral VEC clones: Clone A3, AS, C8 and ElO showed TGF~-induced 
EndMT. Spontaneous EndMT occurred in Clone B8. Clone B6 did not undergo EndMT when 
treated with TGF~ 
Mitral Valve Interstitial Cells-
This level of characterization has not yet been applied to the mitral VICs, nor has 
an extensive literature been published on the topic of cultured VICs. Yet, a wide range of 
phenotypes of VICs has been detected in situ in normal and diseased human and sheep 
valves. It has been established that healthy valve interstitial cells exhibit a quiescent, 
fibroblast like phenotype, expressing vimentin with very little aSMA (myofibroblast 
marker); in contrast, diseased valves display an increased number of aSMA positive cells 
[72]. Therefore, we defme "healthy" valve interstitial cells as vimentin positive/aSMA 
negative/CD31-negative and diseased or "activated" VICs as vimentin positive/aSMA 
positive/CD31-negative. Our lab has characterized ovine mitral VICs by both phenotypic 
and functional assays. In our experience, we have encountered two major categories of 
VIC clones, the quiescent VIC clone (aSMA-negative/CD31-negative) and an activated 
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VIC clone (aSMA-positive/CD31-negative). Figure 3.4a shows examples of a quiescent 
VIC clone and an activated VIC clone. Figure 3.4b shows VE-Cadherin (left column) and 
aSMA (fight column) flow cytometry results of a panel of VIC clones. While some VIC 
clones appear to express VE-Cadherin, when compared to VEC clones, the expression of 
VE-Cadherin is minimal. 
Mitral VICs have been further characterized by immunofluorescence staining 
using the endothelial markers VE-cadherin and CD-31, and the mesenchymal markers 
aSMA and vimentin. We have confirmed that each of these antibodies reacts with the 
ovine homolog. As shown in Figure 3.5, the mitral VIC clones in culture express both 
vimentin and aSMA, but not the endothelial cell markers VE-cadherin and CD31. While 
we do observe slight VIC VE-cadherin expression via flow cytometry, we know that flow 
cytometry is very sensitive, as is evident from flow vs. WB analysis of the VEC clones. 
Therefore the discrepancy between our flow and IFF data can be attributed to this 
sensitivity. These results correspond with observations in the literature regarding the 
heterogeneous nature of VICs and the various phenotypes that are present in the valve 
[61]. 
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Figure 3 .4. Flow cytometry characterization of mitral VICs. 3 .4a. CD31 and a SMA expression in 
three different VIC phenotypes ranging from quiescent (CD31-/SMA-) to activated 
(CD31 +/SMA+). IgG matched controls are show on the left hand column Figure 3.4b. VE-
Cadherin and aSMA expression of a panel of VICs including the primary culture. All clones stain 
positively for aSMA and have little to no expression of VE-Cadherin. A mitral VEC clones is 
shown at the bottom as a positive control for VE-Cadherin. 
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Figure 3.5 Characterization of mitral VICs. The top row illustrates cell morphology. The bottom 
three rows are cells irnmunostained with anti-VE-cadherin, anti-u-SMA and anti-vimentin 
followed by secondary antibodies conjugated to FITC (green fluorescence). Nuclei stained with 
DAPI (blue). The results indicate that these interstitial cells do not express the endothelial 
markers CD31 and VE-Cadherin, but express both uSMA and vimentin 
VIC Functional Properties: Collagen production: 
We conducted functional studies to confirm reports regarding VIC ECM 
production and contractility. We hypothesize that "activated" and "quiescent" VICs 
express different degrees ofECM production and contractile phenotypes. For example, 
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whereas quiescent fibroblasts may contribute to basal ECM production, activated 
myofibroblasts (responsible for tissue remodeling) are implicated in fibrosis and disease 
states, and may therefore express higher collagen production and greater contractility. 
Collagen Prod'uctlon (Cellular) Collagen Production in Supernatant 
Figure 3.6 Results of 3H-proline assay to compare both total cellular (left) and secreted collagen 
production (right) in a variety of cells. The cells were treated with 3H-proline (in proline free 
media DMEM)for 4hrs and then given a 24hr recovery period during which time incorporation of 
3H-proline into newly synthesized collagen continues. The fibrocytes and mitral VIC primary 
culture produce the largest amounts of collagen 
We developed a tritiated proline assay to quantify total collagen in our cells. The 
main use for the amino acid proline is in the production of collagen, and therefore, by 
adding radioactive proline into the cell media, we were able to track incorporation of the 
3H-proline into the collagen. Measuring the amount of radioactivity in the different 
fractions correlates with collagen released in the media (supernatant) and incorporated in 
and around the cell layer (cellular) [128] . 
For comparison, we also tested fibrocytes, bone-marrow MSCs, and ECFCs 
which all produce some level ofECM. As shown in Figure 3.6, the mitral VICs produce 
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comparable amounts of intracellular collagen to the positive controls, whereas all of the 
cell types secrete some amount of collagen into the supernatant. 
VIC Contractile Activitv: 
A challenge the Mayer lab has faced is excessive contraction of TEHV s implanted 
in sheep, such that leaflet size no longer matches the annulus, and regurgitation occurs. 
Contraction, as well as increased deposition of collagen has also been observed in vitro 
prior to implantation [129]. We hypothesize that the excessive contraction was due to the 
mesenchymal cells used to create the TEHV. To assess contractility ofVICs, we have 
developed a free floating collagen gel assay where cells are seeded into a collagen gel 
and gel surface area is measured over time, as shown in Figure 3.7. To optimize the 
contraction assay we tested the parameters of cell and collagen concentration as shown in 
Figure 3.8. We observed that the low concentration (2mg/rnl) of collagen cells contracted 
too rapidly for comparison of different conditions, whereas the high concentration 
( 4mg/ml) did not contract at all. From this data we therefore selected our optimal 
conditions of 2xl 05 cells/gel at 3mg/ml for subsequent experiments. 
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Figure 3.7. Schematic of collagen gel contraction assay indicating the method of quantification 
via measuring surface are of gels over time. During optimization three concentrations of collagen 
were tested (2, 3, 4mg/ml), and two concentrations of cells (2 and 4x l 05cells/gel). 
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Figure 3 .8. Optimization of collagen gel contraction assay: Varying both cell number (2 and 
4xl 05 cells/gel) and collagen concentration (2, 3, and 4 mg/ml) affects the speed and extent of gel 
contraction 
In Figure 3.8 we have measured cell-mediated collagen contraction by tracking 
the change in surface area. This is the conventional method of measuring percent 
contraction in this collagen gel assay, [130, 131] but it provides a two dimensional 
analysis of a volumetric change. We needed to measure the correlation between 2D and 
3D contraction to confirm this two dimensional analysis as a sufficient measurement of 
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contractility. Therefore we measured both surface area and volume in the same cells; gels 
were measured with our conventional 2D imaging techniques, and then gels were fixed in 
4% paraforrnaldehyde for 24hrs and weighed. The reduction in weight was found to 
correlate with the reduction in surface area (Figure 3 .9), thus validating the use of 2D 
percent area contraction as an llidicator of cell contractility. 
10 20 
llme (hours) 
- Percent Area Contraction 
..... Percent Volume Reduction 
30 
1-'='~~--"--'~~~~--------'-~--==-=-----·--·········------1 
• Percent Area contraction 
• Percent Volume Reduction 
Figure 3.9 Correlation between volumetric vs. area contraction in the free-floating collagen gel 
contraction assay. Gels were dehydrated and volume measured to compare with area contraction. 
In the top panel a time course reflects close correlation between area and volume. The bottom 
panel indicates a matching trend for area contraction and volume reduction for four different 
samples. 
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We used a rheometer to assess physical stiffness and the viscoelastic properties 
governing the collagen gels. The storage modulus, G', and loss modulus, G' ', was 
measured for each gel between 10-3 and 10-1 strain units at 0.5 Hz oscillation frequency. 
G' represents the elastic contribution to the gel's resistance to deformation, while G" 
represents the viscous contribution. A representative example of raw data, showing 
changes in _G' over the range of strain tested for each individual gel is shown in Figure 
3.1 Oa. Collagen showed a drop in stiffness above 10-2 strain units, at all concentrations, 
and thus exhibits strain softening at high deformations. To compare the average stiffness 
of each gel formulation at low strains, the raw data for the modulus of each individual 
collagen gel preparation was averaged from 10-3 to 10-2 strain units, as shown in Figure 
3.10b. Collagen gels at 3 and 4mg/ml were found to have similar G' values around 110 
Pa, while 2 mg/ml was significantly softer at 25Pa. 
To describe the relative contributions of the elastic and viscous components of gel 
stiffness, we considered G and G' as orthogonal vectors related by angle 8, the phase 
shift. Thus, tan 8 = G' /G' ', and a small 8 value indicates predominance of elastic effects, 
while high 8 indicates a relatively viscous gel. We plotted 8, averaging among the gel 
preparations, as shown in Figure 3.1 Oc. The 2 and 3mg/ml collagen gels phase shift 
angles of approximately 7-1 oo over all strains tested, indicating the dominance of elastic 
behavior of this gel. The higher concentration of collagen has a 8 value of roughly 15°, 
greater than the 2 and 3mg/ml collagen gels, but still indicating predominantly elastic 
behavior. 
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Figure 3.1 0. Rheological characterization of collagen gels used in gel contraction assay. A. 
Representative raw data of storage modulus (G') from 1 o-3 to 1 o-1 strain units for three 
formulations of collagen gel (2, 3 and 4 mg/ml). B. Average values of storage modulus, G' (red 
bars) and loss modulus, G'' (blue bars) for each concentration of collagen from 1 o-3 to 1 o-1 strain 
units. C. Phase shift 8, for each collagen gel formulation. 
To confirm the contractile nature of the VICs we required a point of reference and 
therefore tested a panel of cells including mitral VICS, VECs, endothelial colony forming 
cells (ECFCs), and BM-MSCs. The endothelial cells (MVECs and ECFCs) exhibited 
little to no contractile behavior. Conversely the mitral VICs and the bone marrow MSCs 
all display contractile behavior, indicative of their myofibroblast-like nature. All three of 
the mitral VIC clones in Figure 3.11 have tested positive for aSMA expression, which 
confirms their activated phenotype. 
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Figure 3 .11. Gel contraction assay comparing the contractile activity of several different cell types 
including ECFCs (blue), mitral VECs (yellow), and three mitral VIC clones (black, red, and green). 
VICS are sensitive to a variety of chemical stimuli that can alter their phenotype 
from a quiescent to an activated state. TGF~ is one of the principle stimulators that can 
cause myofibroblast activation, as evidenced by an increase in aSMA expression and 
changes in stress fiber alignment with a direct effect on VIC contractility [67]. There are 
several other potent agents that can increase VIC contractility, including endothelin-1, 
noradrenaline, adrenaline, the thromboxane, A2 mimetic U46619, 5-hydroxytryptarnine 
(5-HT), histamine, L-epinephrine, bradykinin, isoproterenol, carbachol, [60, 75] [74]. We 
selected TGF~ in order to validate our gel contraction model. When we supplemented the 
VIC contraction media with TGF~ at 2ng/ml, we observed a significant increase in 
contraction for a number of different VIC clones, as shown in Figure 3 .12. This confirms 
that our contraction assay accurately reflects reports in the literature concerning 
modulation of VIC phenotype. 
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Figure 3 .12. Gel contraction assay of four different mitral VIC clones treated alone (blue, red, 
green and purple lines) or treated with TGF~ at 2ng/ml(black line) during contraction assay. All 
four clones display increased contractile activity when treated with TGF~. 
Human mitral VECs are responsive only to TGF~2, and will not undergo EndMT 
iftreated with other isoforms ofTGF~ [51]. Sheep VECs lack this specificity and will 
undergo EndMT regardless of TGF~ subtype. We wanted to determine if the sheep mitral 
VICs are also sensitive to all three isoforms of TGF~ and therefore treated the VICs assay 
with all three isoforms of TGF~ and then monitored contraction. As shown in Figure 
3.13, the mitral VIC clones do not display any specificity for TGF~ isoforms in this 
contractility assay. 
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Figure 3.13. Gel contraction assay of mitral VIC clone 7 untreated (red line) or treated with three 
isoforms ofTGF~ (black lines). 
A further validation of our gel contraction assay was to determine if we could 
distinguish between quiescent and activated VICs. We tested cells isolated from fresh 
tissue to determine how they compared to mitral VICs that had been grown in culture. 
Healthy adult valve interstitial cells exhibit a quiescent, fibroblast like phenotype, 
expressing vimentin with very little aSMA (myofibroblast marker) [71]. In vitro 
culturing adapts the phenotype of ovine valve interstitial cells from a quiescent, aSMA 
negative phenotype, to an activated myofibroblast like phenotype, expressing aSMA and 
myosin and a contractile phenotype [67, 71, 73, 81]. This aSMA positive phenotype has 
been observed in 50% to 78% of cells isolated from intact heart valves and cultured in 
vitro [66, 67]. It is therefore established that culturing VICs on a stiff2D tissue culture 
plates increases their activation and expression of aSMA, thus highlighting the role that 
substrate stiffness plays in modulating cell phenotype. We tested these freshly isolated 
VICs and as Figure 3.14 illustrates, these cells did not have the same contractile ability as 
the cultured cells. This validates the use of our assay in distinguishing VIC phenotype. 
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Figure 3.14. Collagen gel contraction assay of mitral VICs freshly isolated from a valve. 
Untreated (square marker) and cells treated with TGF~ (triangular marker) are indistinguishable 
from the acellular negative control. 
aSMA and Cell Cycle Regulation: 
Characterization of the VICs has revealed heterogeneity within our clonal 
populations. We hypothesize that this heterogeneity in aSMA expression may be due to 
differences in cell cycle phase- i.e. , cells that are activated (high aSMA) could be in the 
proliferating, S/G2 phase of the cell cycle, and quiescent (low aSMA) could be in 
GO/G 1 phase. There is evidence that quiescent VICs may be stalled in G2/M phase and 
exhibit lower proliferation rates than activated VICs [132]. To test a correlation between 
aSMA expression and stage of cell cycle a mitral VIC clone and the primary culture were 
co-stained for aSMA and DAPI. DAPI staining is used for quantification of cellular 
DNA, which is increased two fold in replicating cells. With flow cytometry it was 
possible to apply a DAPI quantification model to designate the VIC populations into the 
different stages ofthe cell cycle: Gl , G2, and S. We could then analyze the aSMA 
expression levels in these subpopulations to detect any trends. In Figure 3.15 the DAPI 
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cell cycle analysis has been applied to the two VIC populations, and the expected 
percentages of cells in each cell cycle phase are displayed. We then performed further 
analysis on the total population to identify the a SMA expression of each of these 
subpopulations, and a representative analysis is shown in Figure 3.16, where the G2 
population is highlighted. We observed no obvious connection between aSMA 
expression and cell cycle phase; the aSMA expression of the G2 phase cells was 
normally distributed within the entire cell population. This observation was consistent 
across all other phases of the cell cycle. We therefore concluded that aSMA expression is 
not dependent on the proliferation and cell cycle stage in the mitral VICs. 
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Figure 3.15. aSMA expression and Cell Cycle analysis of mitral VIC clone and primary culture. 
The top panel displays the aSMA expression the two VIC populations detected via flow 
cytometry. The bottom panel displays the distribution of cells into the different phases of the cell 
cycle via analysis of DAPI staining of DNA. The percentage of cells in each phase is listed below 
the DAPI staining graph. 
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Figure 3.16. On the left, flow cytometry ofDAPI-labeled VIC shows cells in Gl, Sand G2/M of 
the cell cycle. G 1 is labeled P3 and G2/M is labeled P4. Panels on the right show flow cytometry 
of VIC stained with anti-aSMA. aSMA positive cells in G2/M are shown in yellow. 
Conclusions: 
The characterization of these VECs and VICs establishes a baseline cell 
phenotype that is critical for subsequent sections of this study. By establishing VEC and 
VIC phenotype we will now attempt to understand the mechanisms of maintaining a 
' healthy' phenotype in vivo, and how cell-cell interactions affect this phenotype. 
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Chapter 4: Inhibition of Endothelial to Mesenchymal Transformation in Mitral 
Valve Endothelial Cells 
We hypothesize that the healthy native valve is maintained in homeostatic balance 
VEC 
CD31•JaSMA-
I ? 
I . 
I 
.. 
CD31•JaSMA+ 
EndMT 
Figure 4.1. Hypothesis of mitral VIC influence 
on mitral VECs 
by the inhibition of EndMT (Figure 4.1) and 
the suppression of VIC activation. We 
hypothesize that this balance is maintained by 
paracrine interactions between the two cell 
types via active molecules. Nearly all of the 
valvular cells are derived from the valve 
endothelium during development through 
EndMT. The VECs are sensitive to alterations 
in their environment and we have observed the plasticity of mitral VECs - their ability to 
undergo a TGF~ induced EMT [51], and to further differentiate towards osteogenic and 
chondrogenic phenotypes [52]. It has also been observed that VECs communicate 
effectively with one another via surface receptors [ 40, 92], and they possess the ability to 
regulate one another's phenotypes in vitro. We hypothesize that this regulation 
contributes to the maintenance of homeostasis in the healthy valve, and would be 
important to incorporate in TEHV s. Our goal is to learn more about this communication 
between cell types to determine which factors are most relevant for maintaining a healthy 
phenotype in the valve. I will address this using ovine mitral VEC and VIC in a variety of 
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in vitro assays. To determine ifparacrine factors are produced that can influence cell 
behavior and phenotype I used an indirect co-culture assay. 
Indirect Contact: 
Figure 4.2. Transwell™ plate describing the 
indirect co-culture method used to study the 
effects ofVICs on EndMT in the VECS. 
We have developed an indirect co-
culture platform to study how VECs and VICs 
influence each other in culture. One cell type is 
placed in the insert above the filter (see Figure 
4.2) and the other cell type is placed below. 
Diffusion of soluble factors can occur across 
the 0.4~-tm filter. In the valve leaflet, endothelial cells are separated from the interstitial 
cells by ECM, with limited to no direct contact. Thus, the Transwell™ platform can be 
used to model this in vivo environment by allowing for diffusion of soluble factors, but 
inhibiting cell migration or extension of cell processes through the pores. Using the 
Transwell™ system we tested whether or not aSMA positive VIC can inhibit TGF~ 
induced EndMT. 
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Figure 4.3 The proliferation of mitral VECs and 
VICs co-cultured for 48hrs either alone, in the 
bottom of the well (red bar), or in the transwell 
insert (blue bar) of the transwell plates. 
The first step in investigating the 
effects of co-culture on the process of 
EndMT in the VECs is to confirm that the 
use of this co-culturing system does not 
affect cell phenotype and proliferation 
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Figure 4.4. Effect of indirect co-culture on TGFP 
induced EndMT in the mitral VECs. Western blot 
demonstrates VE-Cadherin and aSMA 
expression of VECs grown alone (Jane 1 ), in co-
culture with MVIC (Jane 2), treated with TGFP 
for 5 days (lane 3), or treated with co-culture and 
TGFP (Jane 4). Densitometry of aSMA 
expression normalized to P-Actin is quantified in 
the bar graph for each sample. 
rate. To address this question we have cultured the cells both on the bottom ofthe six 
well plates as well as on the Transwell™ inserts to assess their proliferation rates in these 
two environments (Figure 4.3). The Transwell™ inserts are made from polyester, and 
I 
while all surfaces for cell culture are coated with 1% gelatin, the difference in insert 
material or composition could affect the cells. As we have observed in Figure 4.3, it 
appears that the interstitial cells are more sensitive to the transwell culture system and 
tend to grow faster in the bottom of the transwell plates. Due to the slight inconsistency 
in growth rates, we chose to move forward with our experiments by placing the cells of 
interest on the bottom of the transwell so as not to negatively affect t.Q.e proliferation 
rates. 
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In our initial experiments we co-cultured the mitral VECs on the bottom of the 
transwell with the mitral VICs in the inserts of the 6-well plates (see Figure 4.2). We 
cultured the cells for five days in the presence of TGF~, at which point the VECs were 
prepared for western blot detection of a SMA, vim en tin, CD31, VE-cadherin, and ~-actin 
(loading control) using the antibodies previously mentioned [52]. Co-culture ofVICs 
with VECs treated with TGF~ for five days resulted in decreased EndMT in the mitral 
VECs (as shown in Figure 4.4) 
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Figure 4.5. Effect of conditioned media vs. co-culture on TGFJ3 induced EndMT in mitral VECs. The 
Western blot demonstrates VE-Cadherin and aSMA expression ofVECs grown for 5 days alone (lane 1), 
in co-culture with MVIC (lane 2), treated with TGFJ3 (lane 3), treated with co-culture and TGFJ3 (lane 4), 
and treated with MVIC conditioned media and TGFJ3 (lane 5). Densitometry of aSMA expression 
normalized to 13-Actin is quantified in the bar graph for each sample 
This raised the question as to whether conditioned media produced by the VICs 
would be sufficient to inhibit EndMT in mitral VECs. To test this, we replaced the VIC 
with VIC-conditioned medium in the co-culture assay shown in Figure 4.5 and compared 
the effectiveness of conditioned media and co-culture. To treat the cells with conditioned 
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media we used sterile filtered conditioned media in a 1 : 1 ratio with fresh media and 
replaced the media every 2-3 days. As you can observe in Figure 4.5, the conditioned 
media was nearly as effective to inhibit TGF~ induced EndMT in the mitral VECs as co-
culturing. With this observation in mind we, chose to move forward using conditioned 
media, as it was more efficient to prepare larger volumes of standardized conditioned 
media in this manner. 
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Figure 4.6. The Western blot demonstrates VE-Cadherin and aSMA expression ofVECs grown for 5 days 
alone (lane 1), treated with conditioned media from four different VICs (lanes 2-5), treated with TGF~ 
(lane 6), treated with TGF~ and conditioned media from four different VICs (lane 7-10). Densitometry of 
aSMA expression normalized to ~-Actin is quantified in the bar graph for each sample 
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As previously mentioned, our lab works primarily with mitral valve clones, in 
order to avoid some of the challenges posed by heterogeneous primary cell cultures. 
Based on the heterogeneity of the VICs (as demonstrated in Chap~er 3), we wanted to 
compare the effect of conditioned media from multiple mitral VIC clones on inhibiting 
the process of EndMT in the mitral VECs. We generated VIC-CM from three different 
mitral VIC clones and from primary mitral VIC. These freshly isolated CMs were added 
to TGF~ treated VEC every 2-3 days tested on mitral VEC. This experiment (as shown in 
Figure 4.6) indicates that conditioned media from all VICs that we tested inhibited 
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Figure 4.7. VIC conditioned media inhibits EndMT in multiple 
mitral VEC clones. Western blot demonstrates VE-Cadherin and 
aSMA expression ofVECs grown for 5 days alone (lane 1), with 
MVIC-7 conditioned media (lane 2), treated with TGFP (lane 3), 
and treated with MVIC-7 conditioned media and TGFP (lane 4). 
Densitometry of aSMA expression normalized to P-Actin is 
quantified in the bar graph for each sample 
EndMT 
We also tested the 
converse of this experiment, to 
determine if multiple mitral VEC 
clones are affected in the same 
manner, in that conditioned media 
from the same mitral VIC clone 
has the ability to inhibit EndMT 
in multiple mitral VEC clones. 
To this point all of our 
experiments had been conducted 
wl.th a single mitral VEC (clone C5), we therefore obtained two additional mitral VEC 
clones and repeated the conditioned media EndMT assay to confrrm our previous results 
(Figure 4.7). 
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To ensure that this inhibition is due to a soluble factor specifically being released 
by the VICs, and not as a result of debris from any cell type we tested the conditioned 
media from a mitral VEC, specifically from the same exact clone (here MVEC-C5). The 
conditioned media from this endothelial clone is not effective in inhibiting EndMT in the 
presence ofTGF~, as is evident from Figure 4.8. This data implies that these interactions 
are cell specific, and only the valve interstitial cells (and potentially other mesenchymal 
cell types) have the ability to inhibit EndMT in the mitral VECs. 
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Figure 4.8. Mitral VEC 
conditioned media does not 
inhibit TGF~ induced EndMT 
in mitral VECs. Western blot 
demonstrates CD31 and aSMA 
expression ofVECs grown for 5 
days alone (lane 1 ), treated with 
TGF~ (lane 2), and treated with 
MVEC conditioned media and 
TGF~ (lane 4). Densitometry of 
aSMA expression normalized to 
~-Actin is quantified in the bar 
graph for each sample 
The process of EndMT inhibition with VIC conditioned media has proven to be 
very reproducible, but it was unclear whether these mitral VEC cells could revert back to 
their initial endothelial phenotype. Work from the Bischoff lab indicates that VECs from 
60 
human pulmonary valves are very plastic in nature, and that EMT can be reversed with 
the addition ofVEGF (see Figure 4.9) [51]. 
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Figure 4.9. Plasticity ofEndMT in the valve endothelial cells. Western blot analysis demonstrating CD31 
and aSMA expression of cells treated first for ten days with either control media (C), TGFP (T), or VEGF 
(V), followed by ten additional days in permutations of these conditions. 
Therefore, we questioned the plasticity ofEndMT inhibition, specifically, whether 
or not the CM must be present from the beginning when TGF~ is added to induce 
EndMT, or if the CM can be added later. To address this question we initiated the process 
of EndMT in the mitral VECs and then attempted to reverse it with conditioned media. 
We treated cells first with TGF~ (5days) and then added conditioned media. As observed 
in Figure 4.10, ifwe compare the cells treated with TGF~ for 8 days, with the addition of 
conditioned media (column farthest to the right) with cells treated with TGF~ for either 5 
days or 8 days, it appears that conditioned media was effective in combating the effects 
of TGF~, even after the process of EndMT had already been initiated. 
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Figure 4.10 Western blot ofVEC CD31 and aSMA expression grown for 5 days alone (lane 1-2), treated 
with VIC conditioned media for 5days (lane 3), VIC conditioned media for 8 days (lane 4), TGF~ for 5 
days (lane 5), co-culture and TGF~ for 5 days (lane 6), TGF~ for 8 days (lane 7), and TGF~ for 8 days 
total with VIC conditioned media added at day 5 (lane 8) . Densitometry of aSMA expression normalized 
to ~-Actin is quantified in the bar graph for each sample 
Immunofluorescence 
Our data has indicated that either conditioned media from VIC or co-culture with 
VIC effectively block aSMA expression in mitral VECs treated with TGF~, which would 
indicate an inhibition ofEndMT. We validated our observations using additional 
approaches and assays, the first of which is immunofluorescence. Figure 4.11 shows 
representative images and quantification for aSMA staining of cells treated with 
combinations of conditioned media and TGF~. The results are consistent with what we 
observed by western blot. Interestingly, in this particular experiment, when conditioned 
media from the primary VIC culture was used to block EndMT it was less effective. 
While this may seemingly contradict prior results (see Figure 4.6), it is possible that the 
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conditioned media from the primary culture is less potent than conditioned media from 
clones because of the mixture of different types of interstitial cells in the population. 
MVIC7 Conditioned 
Media+ TGF~ 
Primary Culture 
Conditioned Media+ TGF~ 
Figure 4.11 Mitral VECs stained with anti-aSMA grown in EBM-B (top left) treated with TGF~ (top right) 
and TGFa and conditioned media from a VIC clone (bottom left) and the primary culture (bottom right). 
aSMA in FITC (green) and nuclei in DAPI (blue) 
Testing Endothelial Function: LDL uptake 
The working hypothesis explored in the previous sections is focused on the 
inhibition of EndMT in the mitral VECs treated with conditioned media from mitral 
VICs. For true inhibition ofEndMT, these mitral VECs would retain their ability to 
function as normal endothelium as compared to the cells treated with TGFB alone. We 
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chose to assess endothelial function using a variety of mechanisms, the first being 
acetylated LDL- uptake. Endothelial cells possess the scavenger pathway for 
metabolizing acetylated-low density lipoprotein (Ac-LDL). Lipoproteins such as AC-
LDL can be labeled with 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine 
perchlorate (Dil), a highly lipophilic molecule with can be covalently bonded to 
lipoproteins without altering their surface charge. When cells internalize these labeled 
lipoproteins, the cell enzymes degrade the lipoprotein, and the Dillabel will accumulate 
in the lysosomal membranes, and can thus be imaged [133]. Uptake ofDil-labeled 
acetylated LDL is a function associated with endothelial cells [134], but not with 
pericytes or smooth muscle cells [133]. 
We hypothesized that if EndMT would correspond to a loss in endothelial 
function, and thus a diminished ability to endocytose Ac-LDL; inhibition ofEndMT 
would correspond to a retention in this activity. When we treated all four of the 
conditioned cells with Ac-LDL, we observed that all of the cells were able to take up Ac-
LDL, as compared to mitral VICs, which we used as a negative control (see Figure 4.12). 
We observed that the cells treated with TGF~, and TGF~ +Conditioned media both 
internalized similar amounts of LDL, which would indicate they still express functional 
scavenger receptors on their cell surfaces. We therefore conclude that perhaps using Ac-
LDL uptake is not the optimal tool for assessing endothelial function in these cells 
because the TGF~ treated cells have not progressed far enough in the process of EndMT 
to have lost the ability to uptake LDL. 
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Figure 4.12. Uptake of Texas Red labeled acetylated LDL (red) in mitral VECs treated with EBM-B (top 
left), VIC conditioned media (top middle), TGF~ (bottom left), and VIC conditioned media plus TGF~ 
(bottom right) . MVIC are shown at right as a negative control for LDL uptake. Nuclei are stained with 
DAPI (blue) . 
Testing Endothelial Cell Function: HL-60 Leukocyte Adhesion 
We next measured endothelial cell function in a leukocyte adhesion assay. A 
critical property of endothelial cells is their ability to upregulate the leukocyte adhesion 
molecules E-selectin, ICAM-1 and VCAM when treated with tumor necrosis factor 
(TNFa), a critical function needed to attract leukocytes to sights of infection. In this assay 
we used HL-60 cells, a human promyelocytic leukemia line that adhere specifically to 
endothelial leukocyte adhesion molecules on valve EC as well as many other types of 
cultured EC. We treated the mitral VECs with the four combinations of stimuli: cells 
alone, cell + conditioned media, cells + TGF~ and cells + Conditioned media+ TGF~, 
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and then stimulated them with TNFa for four hours. Following stimulation we added HL-
60 cells to our mitral VECs and allowed them to adhere for 45 minutes before washing, 
fixation and quantification of adherent leukoctyes. The results (shown in Figure 4.13) 
revealed a strong adhesion of the HL-60 cells to both cells alone and cells treated with 
conditioned media. Prior treatment of these cells with TGFP abrogated the binding of the 
leukocytes to stimulated VECs. In cells treated with both conditioned media and TGFP 
we observed a modest increase in leukocyte adhesion as compared to cells + TGFp, 
indicating retention of some endothelial cell function. The images in Figure 4.13 are 
representative of one experiment, while the bar graph represents the average of two trials 
of the adhesion assay, with different MVEC clones (with corresponding error bars). 
These results are consiste.nt with the partial inhibition ofEndMT we have observed from 
our western blot data. 
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Figure 4.13. Binding ofHL60 cells to MVEC treated with EBM-B alone, VIC conditioned media, TGF~, 
and VIC conditioned media plus TGF~ for 6 days. Cells were stimulated with lOng/ml TNFa prior to HL60 
binding. The fold increase in leukocytes adhered/cell for each condition as averaged over two separate 
experiments is shown graphically. 
qPCR results: 
There are several markers that are induced during EndMT in different model 
systems. We developed ovine-specific primers for their mRNA transcripts to provide 
additional markers in addition to aSMA. The primers were designed using DNA 
sequence databases for ovine and bovine genes (which often have very high rates of 
homology). The primers we have validated are: snail (Snaill), slug (Snail2), NFATcl 
and MMP2. These markers have all been demonstrated in the literature to be associated 
with EndMT [135]. Snail-1 [136] and Slug/Snail-2 are zinc finger transcription factors 
that are thought to contribute to the initiation ofEndMT by inhibiting cell-cell adhesion 
transcripts [36, 137] [138], and both are required for valvular EndMT [36]. Nfatcl is 
inversely expressed as compared to snail and slug, and has been shown to inhibit EndMT 
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by suppressing transcription of snail and slug [139]. And finally, matrix 
metalloproteinase 2 (MMP2) has been implicated in EndMT, and has been identified in 
the EndMT regions of the atrioventricular canal of the avian heart where heart valve 
progenitors form [140-142]. 
In our studies we used conditioned media from mitral VICs to treat mitral VECs 
cultured for five days in the presence of TGF~ to induce the process of EndMT. These 
experiments involve growing cells in triplicate in a 24-well plate and pooling samples 
together to obtain RNA measure the four EndMT markers Snail, Slug, NFATcl and 
MMP2. These experiments were run four different times, using different mitral VEC 
clones, but conditioned media from the same VIC to confirm that this phenomenon that 
we observed via western blot is reproducible with multiple clones. The results in Figure 
4.14 illustrate the fold change in expression of these markers in different clones treated 
with different conditions. These four panels represent data from all four clones, to 
demonstrate the overall trend we observed in our data. We observe a similar trend for 
snail, slug and MMP2, in that treatment with TGF~ increases expression of these markers 
as expected, whereas treatment with TGF~ and conditioned media abrogated the increase, 
consistent with an inhibition ofEndMT. The expression ofNFATc1 is modulated 
inversely as compared to the other genes. We do observe a fair amount of variation 
among the behavior of each clone, but this can be explained by the fact that this data is 
derived from multiple clones and multiple experiments, and one cannot expect the 
behavior of all the clones to be identical. 
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Figure 4.14. qRT-PCR results from mitral VECs treated with EMB-B alone, VIC conditioned media, 
TGF~, and VIC conditioned media plus TGF~. The graphs represent the fold increase in expression of the 
four EndMT markers Snail, Slug, MMP2 and nFatcl in different MVEC clones from four different 
experiments. 
Mechanisms: 
The combination of data from this chapter would indicate that some component of 
the conditioned media from mitral valve interstitial cells has the ability to inhibit TGF~ 
mediated EndMT in the mitral VECs. Looking towards the literature we encountered 
several possible candidates that could be present in the media with the ability to inhibit 
EndMT. Our initial selections included VEGF and bFGF. In our own lab, VEGF 
supplementation to the growth media inhibited TGF~ mediated EndMT in the mitral 
VECs [51]. Additionally, our basal growth media contains bFGF (2ng/ml), and may be 
used as a potential mitogen. In vitro bFGF signaling has been demonstrated to play an 
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important role in maintaining the expression of let-7 miRNA, which prevents TGF~ 
activation and EndMT [143]. 
Due to the lack of ELISA assays that cross react with sheep cytokines and factors, 
we instead chose to check mRNA levels of both VEGF and bFGF in the mitral VICs and 
mitral VECs to determine if the cells were producing higher levels of these growth 
factors which in tum may be secreted in the media and thereby prevent EndMT in the 
VECs. We designed primers based on either the ovine of bovine sequences for bFGF and 
VEGF and then tested a panel of clones, as shown in Figure 4.15. While the expression 
ofbFGF was fairly consistent across both VECs and VICs, the VIC clones had much 
higher expression of VEGF. We therefore selected VEGF for additional testing. 
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Figure 4.15. Gene expression ofbFGF and VEGF (normalized to ~Actin) in different mitral VICs (red 
bars) and VECs (blue bars) 
To test the presence ofVEGF as the active component in the conditioned media 
from the VICs, we obtained a sample of Avastin, a recombinant humanized antibody that 
binds to VEGF [144]. The conditioned media was incubated first with 100ug/ml Avastin 
for 30 minutes before treating the cells in the presence of TGF~. The results, shown in 
Figure 4.16 indicate that the addition of A vastin may have partially blocked the inhibition 
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of EndMT by the conditioned media (comparing the MVEC + Conditioned Media + 
TGFP to MVEC+ Conditioned Media+ TGFP + A vastin). While this data is promising, 
further evidence is necessary to confirm that A vastin has the potential to cross react with 
the ovine VEGF, and in fact is truly blocking the effects of conditioned media. 
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Figure 4.16. Testing for the presence ofVEGF in the conditioned media. From left, western blot analysis of 
mitral VEC treated with EBM-B media alone (lane 1), VIC conditioned media (lane 2), Avastin (lane 3), 
TGF~ (lane 4), VIC conditioned media plus TGF~ (lane 5), TGF~ + Avastin (lane 6), VIC conditioned 
media + A vastin (lane 7), and TGF~ + conditioned media + A vastin (lane 8). Densitometric quantification 
of aSMA normalized to ~-Actin expression is displayed graphically. 
An additional option that we considered for the active conditioned media 
component was HB-EGF, a type I transmembrane protein (proHB-EGF) which is made 
up of a signal peptide, heparin-binding, EGF-like, juxtamembrane, transmembrane, and 
cytoplasmic domain [145] and is important in a number of biological processes from 
wound healing [146] to kidney collecting duct morphogenesis [147]. The HB-
EGF knockout mouse has grossly enlarged cardiac valves, and the HB-EGF mutant 
71 
mouse also has heart valve malformations [148] , suggesting that HB-EGF is a negative 
regulator ofEndMT or of VIC proliferation [145]. HB-EGF is expressed by interstitial 
cells and smooth muscle cells in the bladder, and may play a physiological role in 
regulating the proliferation and regeneration ofurothelial cells [149] . Additionally we 
postulated that HB-EGF could be secreted from the VICs as direct inhibitor ofEndMT in 
the VECs. To test this hypothesis we obtained the diphtheria toxin mutant CRM 197 
recombinant protein to add to our conditioned media experiments (membrane bound 
human HB-EGF is the diphtheria toxin receptor). When we add the CRM-197 protein to 
the mitral VECs, it would bind to any HB-EGF receptors on the cell surface and to HB-
EGF shed into the medium. Results from this experiment are still in progress at the time 
of thesis submission. 
Conclusions/Discussion: 
The results from this study suggest that the mitral VICs play an important role in 
maintaining valve homeostasis by inhibiting the process of EndMT in the mitral VECs. 
This interaction could be played out in the valve as the VICs imposing a constant 
influence upon the VECs to promote the maintenance of healthy endothelium, and to 
inhibit the process ofEndMT and VEC migration in the valve that has been observed in 
pathologic and remodeling valves [106]. 
A limitation of this study is the observation that we have encountered some 
inconsistencies in the different EndMT experiments. For example, in our Western Blot 
experiments we observe the striking absence of aSMA expression in mitral VECs treated 
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with co-culture or conditioned media. This clear inhibition of EndMT is not nearly as 
robust in our acetylated LDL assay, leukocyte adhesion assay, or real-time PCR data, 
where we only observe the inhibition of EndMT in some of our markers. These data 
indicate that conditioned media, while effective, may only partially inhibit EndMT as 
opposed to the full inhibition we had anticipated. 
It is relevant to discuss the inhibition of endothelial markers that we have 
observed in some of the EndMT inhibition experiments. In some of our experiments 
(Figure 4.5, 4.6, 4.7) we observe a decrease in the endothelial markers CD31 and VE-
Cadherin when EndMT is inhibited. If EndMT is inhibited with conditioned media 
treatment we would anticipate a retention of endothelial markers in addition to the 
endothelial function retention we observed in subsequent assays (see Figure 4.12 and 
4.13). This loss of endothelial marker expression may be explained by our observation 
that inhibition ofEndMT is only partial, and we may still observe increases in EndMT 
markers such as snail. Snail has been shown to repress the expression of adhesion 
molecules such as E-cadherin in epithelial cells undergoing EndMT [150], and in our 
case the increased snail expression may have a negative effect on our CD31 and VE-
cadherin levels in the western blot experiments. 
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Chapter 5. Inhibition of Endothelial to Mesenchymal Transformation: 
Application to the Aortic Valve 
The process of endothelial to mesenchymal transformation that has been a major 
focus of this thesis thus far is not restricted to the mitral valve. In our lab and others 
EndMT has also been shown to occur in the pulmonary and aortic valve [50, 51, 124]. As 
previously mentioned, the process ofEndMT is critical during the process of embryonic 
valvulogenesis [151 ], and has also been observed in the mitral valve leaflets as a response 
to chordae tethering due to ischemic mitral regurgitation [106]. While EndMT has been 
implicated in many of these processes, thus far one of the connections that has yet to be 
made is the role ofEndMT in calcific aortic valve disease (CA VD). CA VD is the most 
common valvular heart disease in the developed world. Du~ to its prevalence, 
understanding the underlying pathophysiological mechanisms is vital to develop new 
therapeutic strategies. In this aim of our project we sought to explore how the concept of 
cellular crosstalk and regulation from the mitral valve work applies to the aortic valve, 
specifically to identify the connection between EndMT and CAVD, and to what extent 
cell-cell interactions can affect this connection 
CA VD: the risk 
CAVD has become the most common heart valve disease in the western world, 
affecting nearly 25% of adults over the age of 65 [152]. CA VD is characterized by initial 
thickening of the aortic valve leaflet or fibrosis, which is then followed by the formation 
of atherosclerotic like lesions in the valve. Calcification ensues in these lesions, which 
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eventually leads to aortic stenosis of the valve, causing left ventricular outflow tract 
obstruction [153 , 154]. This calcification is characterized by the presence of cartilaginous 
nodules, mature lamellar bone, inflammation, neovascularization, and disruption of the 
ECM in the valve [155, 156] . While there had been some initial promise ofthe use of 
statin therapies to treat CAVD, they ultimately proved ineffective in clinical trials [157, 
158]. There are currently no medical therapies to prevent or halt the progression of 
CAVD [159]; surgical heart valve replacement is the only approved treatment option. As 
the population continues to age, greater numbers of these surgeries will be required, thus 
increasing the burden to society, as these replacement valves typically only last for 10-
15yrs [4]. 
Calcification is often located in the cuspal region on the fibrosa side of the aortic 
valve, and can lead to stenosis, cusp tearing and incompetence, regurgitation, thrombotic 
events, and endocarditic vegetations [160-162]. Additionally, this process of calcification 
occurs at a much more rapid pace in younger patients as compared to the older 
population, thus necessitating more frequent valve replacement surgeries. Figure 5.1 
describes the progression of aortic valve disease, initiating with prevalent risk factors and 
progressing to end stage CA VD where calcific nodules are clearly visible on the stenotic 
valve. 
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Figure 5 .1. Progression of Calcific Aortic Valve Disease 
CA VD Mechanisms: 
While the symptoms and clinical effects of CA VD have been well defined, how 
calcification progresses in the valve is still unknown. Similar to vascular calcification, 
valvular calcification likely occurs through multiple mechanisms leading to active bone 
deposition by valve interstitial cells [70]. It has been well established that valve 
interstitial cells have the ability to undergo osteogenesis in vivo and in vitro, (as well as 
adipogenesis, chondrogenesis, and myofibrogenic differentiation) [70]. Recently our 
group has discovered that endothelial cells from the mitral valve also have the ability to 
undergo osteogenesis and chondrogenesis [52]. 
Several key processes are thought to contribute to osteogenesis [163, 164], 
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including endothelial dysfunction, inflammation [101], apoptosis [165] and necrosis [166, 
167]. There are many hallmarks of inflammation that have been observed inCA VD, 
including activated valve endothelial cells (e.g. upregulated expression of adhesion 
molecules V-CAM and I-CAM), as well as upregulated levels of inflammatory cytokines 
including BMPs [155]. Another important cytokine is TGFP1, which is thought to play a 
critical role in the process of calcification, as it is upregulated in calcified aortic valve 
cusps in correlation with increased levels of alkaline phosphatase and MMP9 activity 
[103, 168]. Additionally when aortic valve interstitial cells are treated in culture with 
TGFp 1, the process of calcification was initiated (as shown by increased alkaline 
phosphatase levels, increased MMP9 expression, increased MMP2 activity, and increased 
apoptosis) [165, 169] . These proinflammatory cytokines contribute to disruption ofthe 
normal homeostasis in the valve, affecting the balance between matrix metalloproteinases 
and their inhibitors [170], and cathepsins [103], thus damaging ECM integrity. 
In addition to chemical modulators, mechanical contributions to the progression 
of CA VD may include changes in shear stress or hypertension. It has been shown ex vivo 
that elevated stretch of the aortic valve in the presence of osteogenic media can enhance 
calcification in the valve in a BMP dependent manner [87]. Figure 5.2 describes the range 
of factors that are believed to contribute to the progression of CAVD. 
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Figure 5.2. Mechanisms contributing to calcific aortic valve disease 
Markers of CA VD. 
I will use four noncollagenous proteins - osteopontin, osteonectin, osteocalcin and 
Runx2/Cbfa1 -as markers of calcification. These proteins are normally present and 
expressed in a coordinated fashion in calcified bone matrix [ 1 71] and they have been 
detected in cells involved in native and bioprosthetic valve calcification [172] 
Osteopontin, also known as bone sialoprotein I, is an acidic phosphorylated 
glycoprotein with a highly negatively charged central region that has a high capacity for 
binding calcium [173] . Osteopontin has a high affinity for macrophages, it may promote 
their migration by stimulating production of matrix metalloproteinases, and it is 
expressed in macrophages in calcified atherosclerotic arteries and other diseased tissue 
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[174] . Osteopontin has the ability to either promote or inhibit the process of calcification 
making it a very potent regulator of osteogenesis in the valve [172, 174, 175]. 
Osteonectin (or SPAR C) is a glycosylated phosphoprotein important in skeletal 
bone mineralization, as it is one of the most highly expressed matrix proteins in bone. It 
has high affinity for calcium, type I collagen and hydroxyapatite, is thought to be a 
linkage protein between collagen and mineral depositions, and is found in remodeling 
and calcified valves [176, 177]. 
Osteocalcin (or bone Gla protein) has been associated with pathologic 
calcification in atherosclerotic plaques and mineralized valves [178, 179]. Osteocalcin 
has been implicated as an important regulator of mineralization of valves and other 
tissues. It is produced by osteoblasts, promotes bone resorption, and has a high affinity 
for calcium, phospholipid, and hydroxyapatite. It is a strong chemoattractant for the cell 
types involved in tissue remodeling including monocytes, osteoclasts and mesenchymal 
cells [180, 181]. 
Runx2 ( cbfa1) is a master regulator of osteogenesis, as mice with gene mutations 
in runx2 are unable to undergo intramembranous and endochondral ossification and die 
shortly after birth [182]. Runx2 is responsible for activating a number of key markers of 
calcification and osteoblast differentiation including osterix [183], alkaline phosphatase, 
and osteocalcin [184]. Additionally, Runx2 has been localized to lesion sites in sclerotic 
valves from hypercholesterolemic pigs [70] . 
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Osteogenesis in Valvular Cells 
As previously mentioned, both valve endothelial and interstitial cells have the 
ability to undergo osteogenesis in vitro when stimulated with BMPs and TGF~ [52, 163]. 
It is believed there exists a subpopulation of valve interstitial cells with increased 
capability for osteogenesis [70]. Calcified AVs also have increased levels of osteoblastic 
markers such as osteopontin, bone sialoprotein, alkaline phosphatase, and bone 
morphogenetic protein 2 and 4 in at least some VICs [163, 164, 185]. At a cellular level, 
when a VICs are treated with BMP2, it stimulates the expression of Runx2 and 
osteopontin, and VICs from stenotic and calcified human aortic valves have increased 
levels ofBMP2 and TGF~ [169, 186]. This data suggests that both VECs and VICs have 
an inherent ability to play a direct role in the process of calcification inCA VD, but it is 
unknown to what extent each cell type contributes in vivo. In our study, we focus on the 
role of EndMT in CA VD by examining the relationship between EndMT and 
osteogenesis in the valve cells. 
Aortic Valve Cell characterization 
The Bischoff lab has previously reported on aortic valve endothelial cells. The 
aortic VEC were isolated from normal ovine aortic valve cusps, expanded as clonal 
populations, and shown to undergo EndMT in response to TGF~. Since these studies 
were published in 2001 and 2008 (Paranya 2001, Yang 2008), my first objective was to 
verify their phenotype and EndMT capability [50]. The aortic VECs were screened for 
expression of the endothelial markers CD31 and VE-Cadherin, and the EndMT marker 
aSMA. As shown in Figure 5.3 these cells have a robust expression of the endothelial cell 
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markers, and lack any aSMA expression, indicating that they have not undergone 
spontaneous EndMT. 
Gav 1 Wav 1 
Figure 5.3. Phenotypic characterization of aortic valve endothelial cells. Both the Gavl and Wavl 
cells stain positively for the endothelial markers CD31 and VE-Cadherin, but do not express the 
mesenchymal marker aSMA. 
Aortic VICs had not been isolated or characterized in the Bischoff lab. Therefore, 
I plated single cells from a primary culture of aortic valve cells (from the same aortic 
valve specimen used to isolate the clonal aortic VEC), cultured the 96 well plates for 14 
days, and screened the wells for cells with VIC morphology. These cells were expanded 
and characterized with our panel of interstitial cell markers, including aSMA [66, 67], 
vimentin [85, 103] and SM22a [76, 187]. The VIC clones, denoted AVIC-K3, A VIC-KS, 
and AVIC-K6 expressed the interstitial cell markers but did not express the endothelial 
markers CD31 and VE-Cadherin, as shown in Figure 5.4. 
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Figure 5 .4. Phenotypic (immunofluorescence staining) of aortic valve interstitial cells. The three 
AVIC clones (K3, K5, and K6) were stained cells were stained with anti-a.SMA, anti-vimentin, 
anti-SM22a., anti-VEcadherin, and IgG control. 
Aortic Valve Endothelial cells can undergo EndMT 
Once these valve cells had been characterized, the next step was to confirm their 
ability to undergo EndMT, as had previously been published [50]. Based on superior cell 
proliferation rates and overall robust nature, we chose to complete the majority of the 
following experiments using only one ofthese two aortic VEC clones, known as wav-1. 
These were grown in the presence of 2ng/ml TGF~ for 8 days, at which point cells were 
analyzed using western blot, immunofluorescence, migration assays, and qRT-PCR 
markers for EndMT. As demonstrated in Figure 5 .5, aortic VECs treated with TGF~ 
showed marked induction of a.SMA as detected via immunofluorescence (a) and western 
blot (b) . Additionally, the EndMT markers MMP2 and Slug were also upregulated (see 
Chapter 4). The aortic VECs treated with TGF~ displayed an increased migratory 
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phenotype in a Transwell™ migration assay as compared to untreated aortic VECs, (see 
Figure 5.6). The induction of aSMA, Slug and MMP-2 and the increased migratory 
activity are consistent with EndMT. Therefore, the aVECs were validated for use in the 
subsequent experiments. 
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Figure 5.5 Aortic VECs can undergo the process ofEndMT. A). aSMA staining ofVECs treated with 
TGF~ . B). Western blot analysis ofCD31 and aSMA expression ofVECs undergoing EndMT. C). RT-
PCR results of expression of the EndMT markers SMA, MMP2 and Slug 
Wav1 WAvl + TGFb 
Figure 5.6 . Aortic VEC were treated with TGFb for 8 days and then tested for migration towards FBS in 
Transwells with a 0.4um filter 
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Aortic VICs can inhibit TGFB mediated EndMT 
We previously observed that EndMT in mitral VECs is inhibited by interaction 
with mitral VICs. We wanted to determine if this same relationship exists in the aortic 
valve cells. Therefore, aortic VECs were grown in co-culture in Transwells™ in basal 
media (EBM-B) or media supplemented with TGF~ for 8 days. Cells were analyzed for 
aSMA via western blot and immunofluorescence, as well as expression of the EndMT 
markers aSMA, MMP2 and Slug using real time PCR. As observed in the mitral valve, 
all three clones ofthe aortic valve interstitial cells have the ability to inhibit EndMT, as 
demonstrated by the decrease in aSMA staining by immunofluorescence (Figure 5.7a), 
by western blot (Figure 5. 7b) and by the decrease in additional markers of EndMT 
(Figure 5.7c). 
A 
+ + 
+ + 
Figure 5.7. Co-culture with aortic VICs inhibited EndMT in aortic VECs treated with TGF~, as 
demonstrated by the loss of aSMA+ cells detected by immunofluorescence staining (A), decrease in aSMA 
expression via western blot (B), and decrease in mRNA expression of the EndMT markers aSMA, MMP2 
and Slug via qRT-PCR. 
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Increased migratory ability is associated with EndMT. Therefore, we use 
increased migration as a functional read-out ofEndMT. We investigated this migratory 
capacity using two different mechanisms. Firstly, the aortic VECs used in previous 
experiments (VEC alone, VEC + TGF~, VEC + A VIC, and VEC +A VIC + TGF~) were 
subject to a migration assay to determine ifthe reduced aSMA could be correlated with 
reduced migration. Indeed, as shown in Figure 5.8, VECs treated with TGF~ and co-
cultured with VICs were less migratory than VECs treated with TGF~ alone. The second 
approach was to determine ifthe presence of AVICs in the bottom ofthe Transwell™ 
would inhibit migration of the aortic VECs that were previously treated for five days with 
TGF~. While this experiment does not specifically address inhibition ofEndMT, it was 
meant to address one of the downstream effects ofEndMT; migration. As shown in 
Figure 5.8, the presence of aortic VICs did indeed inhibit the migration of aortic VECs 
through the Transwell™ filter, despite the presence of a stimulus (20% FBS). 
a. 
Wav-1 cells preconditioned with 
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Figure 5.8. (a) Inhibition ofEndMT in the aortic VECs co-cultured with aortic VICs is confirmed by loss of 
migratory phenotype characteristic of cells undergoing EndMT. (b) A VICs seeded on the bottom of the 
transwell plate inhibit migration ofVECs undergoing EndMT in the migration assay 
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3D model for EndMT and Calcification: Impetus 
Valvular EndMT has been studied in explanted embryonic cardiac cushions, in 2-
D cell culture and by analysis of valves removed from animal models or human 
histological sections. There have been some attempts to address some of the functional 
aspect ofEndMT, specifically, Butcher's group attempted to assess migration and 
invasion of valve endothelial cells seeded on three dimensional collagen gel, but their 
demonstration of migration was somewhat limited [96]. Our goal is to refine our 2D 
assay to a 3D assay to incorporate invasion and migration - two key steps in EndMT and 
valvulogenesis. Therefore, we sought to design a three-dimensional culture system to 
model the architecture of the native valve whereby we could study the ability of 
.endothelial cells to undergo migration and invasion into a hydrogel, and then use this 
system to examine the relationship between EndMT and calcification. 
3D model for EndMT: Development and Optimization: 
The concept of a 3D model for EndMT was based on expertise in the 
Khademhosseini and Aikawa labs in working with hybrid methacrylated gelatin (GelMA) 
and methacrylated hyalyronic acid (HAMA) hydrogels for culturing valve cells. Gelatin 
is a denatured form of collagen, a natural component of the extracellular matrix, which 
retains many of the natural characteristics of collagen including RGD binding motifs and 
MMP sensitive degradation sites. Methacrylated groups can be added to the amine-
containing side groups of gelatin in order to create a sustrate that when mixed with 
photoinitator, can be light polymerized into a gel with stable properties at 37°C [188, 
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189] . Thus GelMA is a very attractive substance for use in tissue engineering due to its 
tunable, degradable, bioactive collagen like nature that retains cen adhesive properties. 
While collagen is a critical component of the heart valve ECM, our goal is to 
study calcification in the heart valve, therefore we want to mimic the precise area in the 
valve where this process occurs. In calcific aortic valve disease, the process of 
calcification initiates and perpetuates from the fibrosa region of the valve, which, in 
addition to being rich in collagen, also con_sists of glycosaminoglycans. Therefore, we 
have chosen to incorporate another biodegradable natural polymer, hyaluronic acid (HA) 
into our hydrogel. HA is a glycosaminoglycan (GAG) component richly present in 
connective tissues. HA has activity in cell signaling, cell migration [190] and wound 
repair [191]. HA is also an essential component of cardiac jelly in heart morphogenesis, 
which further contributes to its value in studying EndMT, as it provides an ideal 
environment for facilitating this process [192-194]. Similar to gelatin, methacrylated 
groups can be added to HA, creating a methacrylated form HA (HAMA) suitable for 
photo-crosslinking. 
The addition of HAMA to our GelMa hydro gels provides a novel matrix that is 
non-immunogenic, non-thrombogenic, degradable, and has been widely used as wound 
healing dressing, tissue engineering scaffolds, and cell/molecule delivery carriers [195, 
196]. Additionally, the mechanical properties ofHAMA based hydrogels are easily 
tunable by varying the degree to which crosslinking occurs. Two parameters that can be 
manipulated are the photoinitiator concentration and crosslinker concentration [197-
199]. Mechanical properties, including stiffness, swelling ratio and adhesiveness, 
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regulate phenotypic changes (ie spreading, migration, and proliferation) and 
differentiation of various cell types [200] [201], including VICs [202] . There has also 
been evidence that substrate stiffness (specifically in gels) affects the calcification of 
valve interstitial cells. On softer matrices VICs downregulate TGF~ receptor I 
expression, but undergo calcification and apoptosis on matrices with higher stiffness 
(stiffness similar to stenotic valves) [167]. This evidence provides the rationale for 
HAMA-Gelma hydro gels in our model for studying the relationship between EndMT and 
calcification in the aortic valve eels. 
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Figure 5.9a. Structure ofHAMA GelMA components 9b. Photocrosslinking with photoinitiatior and UV to 
create a stable construct 
Figure 5.9 provides an overview of the hydrogel synthesis. First the denatured 
gelatin and hyaluronic acid must be metacrylated on their lysine side chains to produce 
GelMA and HAMA (Figure 5.9a) by incubating with methacrylic anhydride at 50°C. 
These new intermediates are then crosslinked together with the addition of photo initiator 
and UV light (Figure 5.9b). The three variables that determine hydrogel properties are 
88 
amount of crosslink:ing, photo initiator concentration, and crosslinker concentration. 
These properties must be fmely adjusted and optimized to maintain cell viability, 
spreading and proliferation, as gels that are too stiff, or have too small of a pore size can 
constrain cells and alter their phenotype. We have optimized our HAMA-GelMA 
formulation based on variations of these three parameters to determine a range of 
conditions that support cell survival and spreading, as shown in Figure 5.10. 
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Figure 5.10. Representative confocal image of live/dead stain ofhydrogel and quantification ofpercent live 
cells. Data are depicted as mean ±SD. bar: 50 !J.ffi 
Figure 5.11 illustrates the experimental set-up of our system, whereby we cross-
link our hydro gels within the insert of a Transwell™ with 8um pores. Using this system 
we can observe the migration of the valve endothelial cells through the hydrogel and the 
filter, both by imaging the hydrogel, as well as quantifying the number of cells that have 
migrated through the filter (similar to a conventional migration assay). This system also 
allows us to investigate the effects of co-culture by placing the aortic VICS either on the 
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bottom ofthe Transwel™ (indirect co-culture), or embedded within the hydrogel (direct 
co-culture). 
AortlcVICs 
.......... 
Figure 5 .11. Schematic of hydrogel migration assay 
Once the hydrogel was shown to be conducive for cell viability and proliferation, 
we optimized the formulation needed for endothelial cell coverage and spreading. As 
illustrated in Figure 5.12, we observed that the 1% HA and 5% Gelma, with 30 seconds 
of crosslinking, resulted in the optimal surface coverage of the aortic VECs. To study the 
process ofEndMT we require a confluent monolayer of endothelial cells, considering that 
a hallmark ofEndMT is that the endothelial cells lose cell-cell contacts between each 
other and begin to invade and migrate into the valve interstitium. 
1% HA 5% GelMA S%GelMA 
Day7 Day7 
Figure 5.12. Optimization ofHA-Gelma formulation to promote cell adhesion and spreading after 7 days of 
culture. Both samples incorporated 0.1PI, UV: 2.5mW/crn2, UV time: 30sec 
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With optimal hydrogel conditions defined, we next tested the Transwell™ system 
to determine if aortic VECs possessed the ability to migrate through the gel (as our goal 
was to assess functional EndMT in the form if migration). While cell migration is 
facilitated via a number of different processes, including cell traction forces and 
expression of proteases such as MMPs to degrade the matrix [203], a significant limiting 
factor in our system could be the microscopic structure of the Gelma. If our pore size is 
too small, the cells .could be constrained and migration would be severely impeded. We 
therefore tested our conventional EndMT assay on VECs seeded on top of the hydrogel. 
Cells were seeded at a density of20,000cells/cm2 and treated in normal media 
supplemented with TGF~ for 8 days. At the end of 8 days aSMA staining revealed that 
these cells had undergone EndMT (Figure 5.13), as evidenced by positive aSMA 
staining. But confocal imaging and an orthogonal view of the hydrogel revealed that 
these cells had not migrated into the gel. We hypothesized that perhaps the lack of 
stimulus within the gel could explain why no cells had migrated into the gel. To address 
this challenge we could either incorporate a stimulus into the gel (ie FBS or bFGF), or 
place the stimulus on the under-side of the gel. We chose the latter and took advantage of 
the Transwell™ system to do so. 
91 
lHA-SGeiMA 0.1 PI 
Day 1 DayS Day 8 
TGFb- TGFb+ 
Figure 5.13. Evidence ofTGF~ mediated EndMT ofthe aortic VECs when seeded on the 1HA-5Ge1MA 
hydrogel. Cells were seeded at a density of20,000cells/cm2• Gel formulation: O.lPI, UV: 2.5m W/cm2, UV 
time: 30sec 
To provide a stimulus on the opposite side of the cell-seeded hydrogels we placed 
aortic VECs on top of hydro gels of varying thickness. These cells were then treated with 
normal media and normal media supplemented with TGF~ to induce EndMT over five 
days. We supplemented the media on the bottom of the Transwell™ with 20% FBS to 
promote migration of these cells. The number of cells that migrated towards the FBS in 
the bottom well was normalized to the number of cells that migrated in the absence of 
FBS. We observed a significant difference in the migration of cells through the thicker 
gel (Figure 5.14). This suggests that not only do the VECs have the ability to migrate 
through these gels, but that a thicker gel is necessary to delineate the effects of TGF~ 
treatment. Based on these observations, we chose to move forward using the 150!-!m 
hydrogel in our Transwell™ system. 
92 
lSOum gel lOOum gel 
p=0.0035 
~ 400 c 0 
f -r- ~ 
"' "' :E 300 ::E 
.E E 
:;: 200 "' "' 
" " 
., .. 
... ... 
_s 1oo <> E 
"0 "0 
0 ~ 0 
u. 0 u. 
~~ ..... ~~ .... . ~~ ·~ ~~ 
Figure 5.14. Migration of aortic VECs treated with TGFP for 8 days through hydrogels of varying thickness 
Cell migration in the Transwell™ system is quantified by counting DAPI-stained 
nuclei that that have migrated through the large-pore sized (8J.lm) Transwell™ filter (as 
opposed to our co-culture assays which use a small-pore sized filter of 0.4J.lm). Our 
hydrogel system provides an added benefit of imaging the cells as they are 'diving' into 
the gel, to provide a qualitative aspect to this functional property of the cells. As shown in 
Figure 5.15, when aortic VECs are treated with TGF~, their migratory ability is 
significantly enhanced. 
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Figure 5.15. Aortic VECs treated with TGFP display increased migration through bFGF containing lHA-
5GelMA hydrogel as determined by visualization of cell nuclei stained with DAPI. 
Aortic Valve endothelial cells can undergo osteogenesis 
The goal of this study is to elucidate the connection between EndMT and 
osteogenesis/calcification, as aberrant EndMT has been hypothesized as a mechanism 
contributing to CA VD, but the true connection has never been defmitively established. 
To make this connection we had to confirm that the aortic valve cells (like other human 
and ovine valve cells [52, 163]) can undergo osteogenic differentiation. We use several 
methods to validate osteogenesis, primarily the increase in osteogenic markers 
(osteocalcin and osteopontin), increase in alkaline phosphatase (ALP) activity, and the 
presence of alizarin red staining. These three techniques were used to confirm the process 
of osteogenesis in our aortic VEC and VIC clones. As show in Figure 5 .16, the treatment 
of aortic VECs with osteogenic media (1 0% FBS, 1% GPS, and osteogenic supplements 
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(1 11mol/L dexamethasone, 10 11mol/L p-glycerophosphate, 60 1-!mol/L ascorbic acid-2-
phosphate) increased the expression of the marker osteocalcin. 
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Figure 5.16. Aortic VECs cultured in osteogenic media expressed increased levels of the osteogenic marker 
osteocalcin as determined via qRT-PCR (normalized to GAPDH) 
Aortic VICS inhibit Osteogensis in Aortic VECs 
Based on the importance of cell-cell interactions in the process of EndMT, we 
hypothesized that the use of co-culture may modulate the process of osteogenesis. There 
are some indications that cell-cell communications are critical for proper valve function. 
In terms of calcification, when the endothelial layer of aortic valve explants was 
removed, it promoted the formation of calcific nodules [204]. We started by focusing on 
the aortic VECs and seeded them on the bottom of our indirect co-culture Transwell™ 
system. These cells were treated with either normal media (DMEM), or osteogenic 
media, with and without co-culture for 14 and 21 days and analyzed using a number of 
methods, including aSMA staining, ALP activity, Alizarin red staining, and qRT -PCR. 
The results of this experiment are show in Figure 5.17 and 5 .18, and indicate that co-
culture with VICs mitigates the induction of osteogenic markers in aortic VECs. This is 
supported by reduced Alizarin Red staining, reduced ALP activity, and reduced 
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osteogenic markers as compared to aortic VECs alone in osteogenic media. 
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Figure 5.17. Co-culturing aortic VICs with aortic VECs stimulated with osteogenic media inhibits 
the process of osteogenesis in the VECs as demonstrated by decreased Alizarin red staining (top 
row, far right image) as compared to VECs treated with osteogenic media alone (top row, second 
image from the left). Co-culturing also promoted decreased aSMA expression in the aortic VECs 
grown in co-culture with VICs (second row of images). Cells were treated for 21 days . 
Percentage of aSMA positive cells per high-powered field was determined and displayed 
graphically. 
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Figure 5.18. Aortic VECs inhibit the expression of osteogenic markers osteocalcin and osteopontin in 
Aortic VECs treated with osteogenic media as compared to VECs treated with osteogenic media alone. 
Expression of markers was normalized to GAPDH expression. 
We observed that a.SMA staining in these aortic VECs in osteogenic media and 
co-culture was decreased as compared to both the normal media and osteogenic media 
controls. This suggested a potential connection between EndMT and osteogenesis, given 
that both EndMT and osteogenesis are inhibited when cells are placed in co-culture with 
VICs. Does this indicate that these two processes are intertwined? Does EndMT therefore 
lead to osteogenesis? And if EndMT is blocked, will calcification no longer occur? 
The connection between EndMT and Osteogenesis, 
Observations previously made in our lab indicate that mitral VECs may undergo 
EndMT initially to become a mesenchymal cell type that will then express osteogenic 
markers [52]. Other groups have also attempted to make the connection between EndMT 
and osteogenesis, and observed that inflammatory molecules can drive the process of 
EndMT in valve endothelial cells, and that this process may be linked in some manner to 
calcification [96]. There are further indications that EndMT could play a role in 
calcification; there are reports ofupregulated TGF~ (a potent driver of both fibrosis and 
97 
EndMT) in CAVD valves [165, 169], and· increased levels of Twist (an EndMT marker) 
have been observed in the pericalcific regions of stenotic aortic valves [100]. This 
evidence suggests a connection between these two processes, and we propose that 
EndMT is necessary for the process of osteogenesis to occur. 
To test our hypothesis we designed a time-course experiment to analyze the onset 
ofEndMT and osteogenesis in the aortic VECs. We selected three different time points, 
day 1, 7 and 14 to analyze markers of osteogenesis and EndMT in aortic VECs treated 
with normal media, normal media supplemented with TGF~, and osteogenic media. At 
each time point we analyzed samples for aSMA expression, Alizarin red staining, and the 
expression of EndMT markers ( aSMA, Slug and MMP2) and osteogenesis markers 
(osteocalcin, osteonectin, osteopontin, and Runx2). We observed an increase in the 
aSMA expression of cells in the osteogenic media as compared to normal media (Figure 
5.19). Additionally, the expression of our EndMT markers aSMA, MMP2 and Slug 
increased both in the cells treated with TGF~ and OM, and also preceded the expression 
of the osteogenic markers osteocalcin and osteopontin (Figure 5.20). This would indicate 
that EndMT may be occurring prior to osteogenesis in our aortic VECs. 
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Figure 5.19 . aSMA expression in Wav-1 cells is increased in osteogenic media (image on right) as 
compared to basal media (image on left) as determined by immunofluorescence staining. Quantification of 
percentage of positive cells per high power field is shown graphically. 
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Figure 5.20 . Expression ofEndMT markers (aSMA, MMP2 and Slug) and osteogenesis markers 
(osteopontin and osteocalcin) in time course of aVEC cells treated with TGF~ or osteogenic media. The 
EndMT markers increase in cell treatments, but precede the expression of osteogenic markers in the OM 
treated cells 
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Conclusions: 
In this study we have developed a platform to examine potential mechanisms of 
cell-cell and cell-matrix interactions in a 3D environment. We have demonstrated that 
cell-cell interactions may be important in maintaining homeostasis in the valve, not only 
by inhibiting the process ofEndMT, but also by inhibiting osteogenesis in these VECs .. 
We hypothesize on the role of endothelium in the onset of disease, and what goes awry in 
the valve to disrupt this homeostasis. To further study the effect of external factors on the 
valve homeostasis, we propose additional experiments including adding monocytes to the 
media medium to mimic inflammation, damaging the endothelium via a scratch 
assay/treatment with reactive oxygen species (ROS), or the addition of monocytes to the 
medium to evaluate the effect of circulating progenitor cells. These additional 
experiments could help us understand precisely what occurs during the initiation and 
progression of disease, and how these cell-cell interactions are disrupted. This would 
allow us to identify the contributing factors to the initiation of CA VD, and whether the 
process ofEndMT is an initiating event in CAVD. 
While this study has important implications for studying EndMT and CAVD, 
there are still some limitations to our model. The majority of our studies are in a two 
dimensional, in vitro environment, and without in vivo confirmation we can only 
hypothesize as to their relevance. While the use of our 3D migration/co-culture model 
reflects the in vivo environment, it still lacks many physiological parameters including 
dynamic flow, shear stress, and interactions with the bloodstream. Despite these 
limitations, we believe our platform has provided novel information regarding the 
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importance of remodeling homestasis in the valve, and the interplay between VECs and 
VICs that is critical for maintaining a healthy valve phenotype. 
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Chapter 6. Suppression of Mitral Valve Interstitial Cell Activation 
The definition of the valve interstitial cell phenotype has been explored for the 
past decade, but there remains a lack of consensus on what constitutes a valve interstitial 
cell. While an all-inclusive VIC phenotype has yet to be described, it is agreed upon in 
the field is that VICs from native, healthy valves are quiescent, whereas diseased VICs 
become activated (typically identified as an aSMA positive with contractile capability). 
VICs can be induced to an activated phenotype by a variety of mechanisms, including 
chemical stimulus [12] [74, 75, 77, 78, 80], substrate stiffness [83 , 205], and mechanical 
stimulation (shear stress or stretching) [67, 79, 85, 89]. One aim of my project is to 
understand the potential role that valve cell interactions play in modulating the VIC 
phenotype. 
There are limited reports of cell-cell interactions between VECs and VICs. A 
communication network exists between these two cell types [95], and they may be able to 
transduce mechanical signals such as shear stress and pressure through the valve. 
[ 45] [85] [94], but this is the extent of the literature on the topic. We therefore sought to 
use our in vitro indirect co-culture assays to determine if these cells types could modulate 
one another under defmed chemical conditions but in the absence of an added stimulus 
(mechanical forces). Our hypothesis (see Figure 1) is based in part on the observation that 
VICs grown in culture begin to express aSMA and exhibit contractile activity, indicative 
of an activated phenotype. We postulated that loss of intercellular interaction with VEC 
when VICs are removed from their native environment in vivo leads to an activated VIC 
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phenotype. One test of this hypothesis would be to determine of co-culture with VEC 
would restore a quiescent aSMA negative, low contractile phenotype (Figure 6.1 ). 
Quiescent VIC 
aSMA-
Figure 6.1. Hypothesis ofmitral VEC modulation ofVIC phenotype 
Indirect co-culture of VICs 
We studied the valve cell interactions using the transwell experimental set up 
described in chapter 4. Our cell of interest was the VICs, which were plated on the 
bottom of the transwell and treated with combinations of either VECs (in transwell 
insert), and/or TGF~ for five days. When a clone or the primary culture of the mitral 
VICs was exposed to mitral VEC co-culture, we observed a dramatic downregulation of 
aSMA, as shown in Figure 6.2. When TGF~ was added to these growth conditions this 
suppression was abrogated. This suggested that TGF~ signaling was sufficient to over-
ride paracrine factors released from the VEC. We chose to test both a clone and the 
primary culture in this experiment to ensure that our observations with the clones are 
representative of the broader VIC population. 
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aSMA 
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TGF~1 + + + + 
Co-Culture with MVEC4 + + + + 
Figure 6.2. Mitral VEC suppress uSMA expression in VIC clone (lane 2 vs. lane 1) and VIC primary 
culture (lane 5 vs. lane 6); TGF~ ameliorates this suppression in VIC clone (lane 4), and the primary 
culture (lane 8) as determined via protein expression in Western Blot analysis. Densitometric 
quantification of uSMA expression normalized to ~Actin is shown graphically. 
Conditioned Media treatment ofVICs. 
To further study the restoration of the quiescent VIC, we tested if conditioned 
media from mitral VECs was sufficient to induce the same phenotype. We grew VICs in 
their standard culture conditions (1% gelatin coated tissue culture plastic treated plates) 
for 5 days and every 2-3 days treated with VEC conditioned media. Following treatment 
cells were examined via western blot for aSMA expression. 
104 
aSMA 
~Actin 
Cond media MVEC-C4 
Cond media MVEC-CS 
s 
iii 
• [ 
.. 
w 
c 
:;:::; 
u 
t 
II) 
t! 
+ 
+ 
Figure 6.3 . Conditioned Media suppresses aSMA (lanes 2 and 3) as compared to VICs grown alone (lane 
1) indicating restoration of the quiescent VIC phenotype as determined via Western Blot analysis. 
Densitometric quantification of aSMA expression normalized to ~Actin is displayed graphically. 
We wanted to determine how rapidly the suppression of aSMA expression occurs. 
We conducted a time course by treating VICs with mitral VEC conditioned media and 
examed aSMA expression atday 3, 4, and 5. As is illustrated in Figure 6.4, which shows 
western blot and densitometric quantification of the bands, VEC conditioned media 
expression is most effective at the earlier time points. It is notable that the aSMA 
expression of these cells tends to increase over time, and this may be cell density 
dependent [206], or there may be a window of recovery time after plating before cells 
will start to produce aSMA. 
105 
aSMA 
I3Actin 
Day 
Co-culture w/MVEC 
c 
0 
·; 
! 
ca. 
.. 
w 
c 
ts 
.. 
c. 
~ 
3 4 5 3 4 5 
+ + + 
Figure 6.4. Time course of suppression of VIC phenotype via co-culture with mitral VECs. VICs were 
grown alone for 3, 4, and 5 days (lanes 1-3), and in co-culture with VEC for 3, 4, and 5 days (lanes 4, 5, 
and 6) as determined via protein expression in Western Blot analysis . Densitometric quantification of 
SMA expression normalized to ~Actin is displayed graphically . 
Immunofluorescence ofVIC 
The western blot data from co-culture and conditioned media experiments is 
striking, but we wanted to confirm these results using additional techniques. We 
immunostained VIC treated with our without VEC conditioned medium for aSMA and 
an additional mesenchymal marker SM22a. Both SMA and SM22a are smooth muscle 
cell markers that have been used to characterize valve interstitial cells [68, 187]. As 
shown in Figure 6.5 there is a loss in expression of both of these markers in VICs treated 
with VEC conditioned medium. There was a ~50% reduction in the number of aSMA 
and SM22a positive cells when FITC-positive cells were counted and expressed as a 
percent of total cells. 
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MVIC 
MVIC+ MVEC 
Figure 6.5. aSMA and SM22a immunofluorescence staining of untreated VICs (top row) and VIC co-
cultured with mitral VECS (bottom row). Quantification of the percentage of aSMA and SM22a positive 
cells per high power field is displayed graphically. 
Specificity of conditioned media effect on VICs 
We questioned whether the results thus far are specific to VECs, or if any cell 
type can induce a quiescent phenotype? We tested the effect of conditioned media from 
valve interstitial cells on the same valve interstitial cells. Figure 6.6 demonstrates that 
conditioned media from the mitral VIC primary culture is far less effective at suppressing 
aSMA expression in the mitral VIC primary culture, which emphasizes the importance of 
the specificity in these valve cell-cell interactions. 
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Figure 6.6 Western blot analysis of untreated VIC (lane 1), VICs treated with MVEC conditioned media 
(lane 2), and primary VIC conditioned media (lane 3). Densitometric quantification of SMA expression 
normalized to f3Actin is displayed graphically. 
Expanding on the topic of specificity, we questioned whether endothelial cells 
undergoing EndMT (and thus in a transitional state) could still suppress VICs. As shown 
in Figure 6.7, the mitral VECs undergoing EndMT (treated with TGFB and expressing 
aSMA in the WB panel on the right) are just as effective at suppressing the VICs as the 
untreated VECs (WB panel on the left). 
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Figure 6.7. On the right, positive confinnation ofVICs undergoing EndMT, as evidenced by aSMA 
expression in cells treated with TGF~ (lane 2). This conditioned media was used to treat VICs on the left: 
untreated VICs (lane 1), as compared to VICs treated with MVEC conditioned media (lane 2), and 
conditioned media from EndMT MVEC (lane 3). Densitometric quantification of aSMA expression 
normalized to ~Actin is displayed graphically. 
Protein stability in conditioned media 
To facilitate the indirect co-culture assays, we considered whether large batches 
ofVEC CM could be prepared, stored frozen at -20, and thawed for individual 
experiments. To test the temperature sensitivity of the conditioned media components we 
compared fresh vs. frozen media from the same mitral VEC clone on the VICs. As shown 
in the second and third column of Figure 6.8, the frozen media did not appear to be 
capable of suppressing a SMA expression as potent as the fresh media, and therefore from 
this point forward we used only fresh conditioned media. 
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Figure 6. 8. Comparison of fresh vs. frozen conditioned media. Western blot analysis of aSMA and SM22a 
in untreated VICs (lane 1), VICs treated with fresh VEC conditioned media (lane 2), and VICs treated with 
frozen VEC conditioned media (lane 3). Densitometric quantification of aSMA and SM22a expression 
normalized to ~Actin is displayed graphically. 
Reversibility of SMA suppression 
We set up experiments, analogous to those presented for VEC EndMT, to test the 
reversibility of the activated VIC state. We selected day three as our time point for 
analysis, based on our time course result shown in Figure 4. We treated VIC with VEC 
conditioned media for three days, allowed for a two-day recovery period and then 
compared the aSMA levels. In lanes 2 and 4 in Figure 6.9, the suppression of aSMA in 
VIC exposed to VEC conditioned media is apparent as compared to untreated controls at 
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day 3 and 5. In lane 5 cells were treated with conditioned media for 3 days, at which 
point fresh media was added. The reversal of the quiescent phenotype is apparent when 
comparing this lane to lanes 2 and 4, suggesting that the mitral VICs is modulated rapidly 
in response to soluble factors produced by VEC. This suggests that aSMA increases with 
days in culture and that VEC-CM prevents this process. 
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Figure 6.9. Reversibility of mitral VIC suppression. Western blot analysis ofVICs grown for 3 days (lane 
1), treated with VEC conditioned media for 3 days (lane 2), untreated for 5 days (lane 3), treated with 
conditioned media for five days (lane 4), and treated for 3 days with conditioned media followed by two 
days in normal media (lane 5). Densitometric quantification of aSMA expression normalized to ~Actin is 
displayed graphically. 
Additional Markers of mitral VICs. 
VICs have been shown to express fibroblast surface antigen, aSMA, vimentin, 
SM22a, CD44, CD105 (weakly), a1 , a3 , a5 and ~1 integrin [68], calponin [69], and 
desmin [ 65]. With the exception of a SMA and SM22a, it is unclear if expression of these 
markers varies with phenotype, and if they are all present in healthy valves. My goal is to 
identify additional markers that correspond to a specific phenotype (i.e. activated or 
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quiescent) and/or can be correlated with cell function. To do this, we have developed 
RT-PCR primers specific for ovine transcripts, as the number of validated anti-ovine 
antibodies is limited. For VICs we have recently added two new candidates to our 
repertoire of VIC markers: collagen I and chondromodulin. 
Collage I is an important component of the valve extracellular matrix [15], and in 
humans collagen (mostly type I, some type III) accounts for 43-55% of the valve [16]. 
Collagen I is associated with VICs [89, 207], and increased collagen deposition occurs in 
many different valve pathologies that are characterized by fibrosis [103, 208, 209]. We 
hypothesize that activated VICs in culture express higher levels of collagen I, and that co-
culture with mitral VECs could reduce this expression level. 
Chondromodulin is an anti-angiogenic molecule that has been detected in healthy 
interstitial cells in valves that contain little to no vessels [210]. The current understanding 
is that most valves are avascular, and only in the setting of disease do we encounter 
vascularity in the valve.[91, 211]. These vessels are thought to arise secondarily to 
inflammation in the area of the leaflet resulting from diseases such as endocarditis or 
rheumatic fever [211] [91, 212]. Chondromodulin has been implicated as an important 
inhibitor of angiogenesis in valves [213] and the lack of this modulatory protein may 
contribute to vascularity in pathologic valves. Therefore we selected chondromodulin as a 
potential marker for quiescent versus activated VICs. 
We designed primers to test gene expression levels of these two candidate 
markers in VICs. We tested the effects of conditioned media from three different MVECs 
on the primary MVIC culture (4 different experiments), and co-culture of the primary 
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VIC culture with two different mitral VEC clones (2 different experiments). The results 
ofthese experiments are shown in Figure 6.10, and indicate that co-culture ofVIC with 
VEC-conditioned media decreases collagen I expression and increases chondromodulin 
expression. These results are in line with our hypothesis, that mitral VECs have the 
ability to induce a more quiescent/healthy phenotype in the VICs. 
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Figure 6.1 0. Quantitative real time PCR analysis of mRNA levels of collagen and chondromodulin in 
untreated VICs (grey bays), VICs co-cultured with VECs (red bars), and VICs treated with VEC 
conditioned media (blue bars). All treatments lasted 5 days. 
Modulating Contractile Activity of MVICs. 
We hypothesized that changes in the VIC protein and gene expression should 
correlate with changes in fimctional behavior of the mitral VICs. Changes in the 
cytoskeletal proteins aSMA and SM22a could translate into changes in the contractile 
activity of these cells, as there is evidence in the literature that a SMA and SM22alpha 
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play a role in cell contractility in smooth muscle cells [214]. In Chapter 3 we developed a 
free-floating collagen gel assay to measure potential changes in contractile activity of 
these cells. 
To detect changes in VIC contractile activity in response VEC, we co-cultured the 
cells for 5 days and then seeded the VIC in the collagen gel contraction assay. We 
repeated this assay six times with multiple combinations of VIC and VEC clones, and 
two representative experiments are shown below in Figure 6.11. The top line (red) on the 
graph corresponds to mitral VIC clones grown alone, whereas the black line represents 
VICs that were co-cultured with mitral VECs. In both experiments, co-culture with mitral 
VE reduced the contractile activity of the VICs at several time points from 3 hours to 24 
hours. 
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Figure 6.11. Collagen gel contraction assay oftwo untreated VIC clones, Kl9 and Bl2 (red lines), as 
compared to cells preconditioned with MVEC co-culture for 5 days (black lines), and unseeded controls 
(blue bars). 
We used the gel contraction assay to examine the effectiveness ofVEC-
conditioned media. In Figure 6.12, a primary culture of mitral VICs were cultured with 
conditioned media from three different mitral VECs and then assayed in the gel 
contraction assay. All three conditioned medias inhibited mitral VIC contraction. 
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Figure 6.12. Collagen gel contraction assay of untreated VICs (blue lines), as compared to VICs pretreated 
for five days with VEC conditioned media from three different clones (red, pink, and green lines) as 
compared to unseeded controls (black lines). 
Conclusion: 
Experiments with the mitral VECs indicate that the valve cells appear to have a 
default phenotype to which they resort when cultured in minimal growth media. The 
default for VEC in culture is endothelial (VE-cadherin-positive/aSMA-negative) but 
some clonal populations undergo spontaneous EndMT, which may be due to depletion of 
activity of factors in the serum or the bFGF in the VEC growth medium. The default 
pathway in culture for VIC is an "activated" aSMA, low chondromodulin, collagen 
producing phenotype. Our experiments show that both spontaneous and TGF~-mediated 
EndMT can be blocked by soluble factors produced by VICs. The activated VIC 
phenotype can be reversed by co-culture with VEC or conditioned media from VEC. This 
is an exciting observation, as the only other method known to achieve this quiescent state 
is the alteration of substrate stiffness [83], which can also affect cell growth and 
· proliferation. 
The data from this section supports our hypothesis that the mitral VECs have the 
ability to induce a more quiescent phenotype in the mitral VICs, not just on a protein and 
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gene expression level, but also from a functional standpoint (contractility).· This 
emphasizes the importance of an endothelial layer on the valve to maintain the VICs in 
their quiescent state, and that the loss and or dysfunction of this endothelium can 
contribute to VIC activation. We also observed that VECs undergoing EndMT could still 
suppress VIC activation. An in vivo correlation of this observation is that when cells at 
the endothelium ofthe valve are stimulated by some external force-be it mechanical or 
chemical-they undergo EndMT and migrate into the interstitium where they may have the 
ability to suppress VICs that may have become activated by those same external forces. 
This would mediate the return to homeostasis and healthy phenotype, which may have 
been disrupted. 
There are some limitations that could be addressed in this study, primarily 
addressing the ability to translate this information from a two dimensional in vitro study 
to what actually occurs in vivo. These are inherent concerns with using static methods to 
study 3D dynamic phenomenon, but we believe our use of indirect co-culture, multiple 
clones as well as the primary VIC population has helped to capture a fairly accurate view 
of the native VIC population, and that our observation are consistent with in vivo 
observations of the cellular phenotypes in healthy and diseased valves. An interesting 
future study could involve the use of ex-vivo valves to study the effect of disrupting the 
homeostasis we believe exists in the valve, by disrupting/damaging the endothelium and 
determining the effect on VIC phenotype. In terms of calcification, there are some reports 
that removing the endothelium from explanted valves promotes the formation of calcific 
nodules [204], which supports our hypothesis. 
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Chapter 7. Screening of Candidate Cells to Recapitulate Valve Cell Phenotypes in 
TEHV 
The general paradigm of pediatric heart valve tissue engineering involves the 
process of obtaining autologous cells from patients whose congenital defects have been 
diagnosed in utero. These autologous cells are derived from different sources including 
amniotic fluid or the umbilical cord once the child is born. These cells are amplified in 
culture to numbers subsequent for seeding a scaffold, which can be conditioned in vitro 
in a bioreactor prior to implantation. This paradigm represents the approach that has been 
taken in the last 20+ yrs to optimize the TEHV. Despite progress, our lab and others in 
the field have been unable to create TEHV that function past a twenty-week time-point in 
large animal models such as sheep. This has precluded the advancement to clinical trial 
of TEHV in patients. We hypothesize that this failure is due in part to a lack of or 
insufficient VEC-VIC reciprocal interactions. 
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Figure 7.1. Paradigm of tissue engineered heart valves 
TEHV Cell Sources: It has been difficult to identify the ideal cell source or sources for 
TEHV because little is known aboutthe specific properties ofVECs and VICs that are 
required for a valve to function over a lifetime. Many different cell sources have been 
utilized with varying levels of success (see Table 7.1). The functions required ofthese 
cells include proliferation, ECM production/remodeling, non-thrombogenicity, and non-
immunogenicity. Generally, a single cell source has been isolated and expanded for use 
in seeded scaffolds. The selection of cell type has been based primarily on the ability to 
deposit matrix, as many scaffolds are porous, and require large amounts of ECM for 
leaflet integrity and in order to withstand blood flow in the heart. The cell type that has 
been most widely tested in TEHVs is bone marrow mesenchymal stem cells (BM-MSCs) 
[ 1 09] in part because of the feasibility of isolating autologous cells, capacity for 
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proliferation in vitro, ability to synthesize ECM, and potential to differentiate into VICs. 
BM-MSCs have been used to successfully seed conduits for implantation [8], but it is 
unclear as to the fate of these cells over time. In addition to mesenchymal stem cells, 
there are several other cell sources which provide the desirable characteristics of ECM 
production and proliferation capacity. These include fibroblasts [110], smooth muscle 
cells, and amniotic mesenchymal stem cells (AF-MSCs). AF-MSCs are of particular 
interest because they have been successfully implemented for tissue engineering in 
animal models [111, 112] and could be harvested as autologous cells for pediatric TE 
applications when the defect is diagnosed in utero. 
Shlnoka (1995-6) Polyalycollc acid (PGA) Ovlne endothelial cells and fibroblasts Pulmonary valve leaflet (sheep) 
Hoerstrup (2000) P4HB coated PGA Ovlne endothelial cells and myoflbroblasts All three PV leaflets (sheep) 
Steinhoff (2000) Decellularlzed sheep valves OVIne endothelial cells and myoflbroblasts PV conduits (sheep) 
Perry (2003) P4HB coated PGA Ovine MSCs In vitro only 
Sutherland (2005) PGAand PLLA Ovlne MSCs All three PV leaflets (sheep) 
Schmidt (2005) PGA coated with P4HB Umbilical cord myoflbroblasts, blood EPCs In vitro 
Schmidt (2006) PGA coated with P4HB Chorionic villi derived cells, umbilical cord EPC In vitro 
(human) 
Gottlieb (2010) PGA·PLLA Bone marrow-MSC Pulmonary valve conduit 
Table 7.1. Selected summary of scaffolds, cell sources, and sites oftissue engineered heart valve 
implantation in the last 20yrs 
Some of the recent TEHV models have opted out of seeding endothelial cells onto 
the construct prior to implantation, instead relying on in-growth of endothelial cells from 
the pulmonary artery or attachment of blood borne ECFCs. While this method may 
theoretically work, there remains a risk of thrombosis if the process of endothelialization 
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does not occur at a rapid rate. An additional drawback to the method is that BM-MSCs 
may differentiate aberrantly without an endothelial layer, and further, may over-produce 
ECM, leading to thickening, stiffness, and valve contraction. This may explain the tissue 
contraction observed in previous studies in the Mayer lab [8] . There is limited work cited 
in the literature where scaffolds have been endothelialized prior to implantation. The cells 
that have been selected are either ECFCs [10, 14], saphenous vein endothelial cells [113], 
fetal stem cells [114], or carotid artery endothelial cells [215]. These examples have 
either used only endothelial cells, or endothelial cells in conjunction with a mesenchymal 
cell type to seed tissue engineered scaffolds. 
In addition to the role of an endothelium in the prevention of a thrombotic event, 
we hypothesize that the interactions between the VECs and VICs are integral for 
maintaining valve homeostasis. Therefore, it is important to consider sources for the 
"TEHV" endothelial cells in addition to alternative sources for "TEHV" interstitial cells. 
While some data exists comparing alternative cell sources with native valve cells in terms 
ofECM production and other general observations [122], there is no evidence as to how 
these alternative sources might functionally interact with one another. We propose testing 
these cell alternatives to determine how they compare to native valve cells . 
. In this section we screened candidate cells for their ability to properly interact 
with VEC or VIC in the Transwell co-culture model. We assayed endothelial cells for 
ability to suppress the activated mitral VIC phenotype, and conversely, we assayed 
mesenchymal cells for ability to inhibit TGF~ mediated EndMT in mitral VECs. 
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Candidate Endothelial Cells 
We tested two candidate endothelial cells: ovine carotid artery endothelial cells 
(CAECs), and peripheral blood endothelial colony forming cells (ECFCs). These two 
cells types have been used extensively in our lab, and offer potential advantages of being 
easy to isolate and expand in culture [216]. CAECs were isolated by Dr. Melero-Martin, 
and used in the Bischoff lab for comparisons with mitral VECs [52]. In recent studies, 
neither ECFCs nor CAECs underwent EMT when treated with TGF~ 1 [52]. 
We first confirmed the identity of these cells and compared their phenotypes with 
the native VECs. In Figure 7.2 we used phase contrast microscopy and immunostained 
for a panel of markers to compare the CAECs and ECFC s with the native VECs. They 
shared cobblestone morphology, positive staining for CD-31 and VE-cadherin, and 
negative aSMA staining (Figure 7.2), which suggests that these candidate endothelial 
cells are phenotypically similar to the mitral VECs. 
We used indirect co-culture (described in Chapter 4) to test the ability of ECFCs 
and CAECs to suppress the activated VIC phenotype (Figure 7.3), We observed that 
these two endothelial cells possess the same ability to induce a quiescent, aSMA-low 
VIC phenotype as the native VECs. We observed that when TGF~ was added to the co-
culture, neither the CAECs or the ECFCs were able to suppress aSMA expression in the 
VICs. This is the same as what we previously observed with the VEC co-culture, where 
TGF~ was also able to override the co-culture suppression. 
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MVEC-4 MVECS CAEC3 
Figure 7 .2. Phenotype of CAECs as compared to mitral VECs. The top row describes cell morphology from 
phase contrast images. The bottom three rows represent staining of these endothelial cells, which stain 
positively for the endothelial markers CD31 and VE-Cadherin, but stain negatively for aSMA 
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Figure 7.3 . Western blot analysis of VIC primary cells on the left either untreated (lane 1), co-cultured with 
ECFCs (lane 2), or co-cultured with mitral VECs (lane 3). On the right, an untreated VIC clone (lane 7), 
co-cultured with CAECs (lane 8). TGF~ treatment abrogated the effects of this co-culture. Densitometric 
quantification of aSMA expression normalized to ~Actin is displayed graphically. 
To further compare the candidate endothelial cells with the mitral VECs we tested 
the effectiveness of conditioned media from these cells at suppressing VIC activation. In 
Figure 7.4 the VIC primary culture is treated with conditioned from ECFCs, CAECs, and 
mitral VECs. Just like the mitral VECs, the conditioned medium from these two 
candidate cells can effectively suppress VIC aSMA expression. 
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Figure 7.4. Western blot analysis ofVICs treated with candidate endothelial cell conditioned media. On the 
left, untreated cells (lane 1) as compared to cells treated with ECFC conditioned media (lane 2). On the 
right, untreated V!Cs (lane 1) as compared to MVEC conditioned media treatment (lane 2), and CAEC 
conditioned media (Ian~ 3). Densitometric quantification of aSMA expression normalized to ~Actin is 
displayed graphically. 
We next tested the ability of these candidate endothelial cells to inhibit VICs on a · 
functional level by utilizing our collagen gel contraction assay. Conditioned media from 
ECFCs proved just as effective in inhibiting VIC contraction conditioned media from 
mitral VECs and (Figure 7.5). This ability to alter VIC function in addition to phenotype 
indicates that the ECFCs and mitral VECs may be modulating the VICs in a similar 
manner 
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Figure 7.5. Collagen gel contraction assay of primary VICs untreated (blue line), preconditioned for five 
days with VEC conditioned media (red, orange and black lines), preconditioned with ECFC conditioned 
media (green line) as compared to the unseeded control (grey line). 
Candidate Interstitial Cells 
Candidate mesenchymal cells were tested for ability to inhibit TGF~ 1 -induced 
EMT in mitral VECs. Our preferred mesenchymal cell type to test was ovine BM-MSCs 
[8] because the cells are easy to isolate, expand and they share many of the fibroblast 
like characteristics ofthe VICs. 
First we confirmed phenotypic similarities by using phase contrast microscopy 
and immunofluorescence staining. In Figure 7.6 both cell types display spindle shaped 
morphology, stain negatively for the endothelial markers CD31 and VE-Cadherin, and 
positively for aSMA a.t1d vimentin. 
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Figure 7.6. Characterization of candidate interstitial cells. The mitral VIC clone, VIC primary culture and 
BM-MSC all stain negatively for the endothelial markers CD31 and VE-Cadherin, but stain positively for 
both aSMA and vimentin. 
On a functional level, we tested whether BM-MSCs could inhibit TGF~ induced 
EndMT in the mitral VECs. We added conditioned media from the BM-MSCs to our 
conventional EndMT assay. As shown in Figure 7.7, the conditioned media from BM-
MSC inhibited TGF~ induced EndMT in the mitral VECs. Therefore the BM-MSC pass 
our requirement of interacting with the mitral VECs. 
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Figure 7.7. Western blot analysis of aSMA expression in mitral VECs grown in normal media for 6 days 
(lane 1), treated with BM-MSC conditioned media (lane 2), treated with TGF~ (lane 3), and treated with 
TGF~ and BM-MSC conditioned media (lane 4). Densitometric quantification of aSMA expression 
normalized to ~Actin is displayed graphically. 
As a control for the specificity of inhibition in our VECs, we wanted to confirm 
that our candidate endothelial cells (ECFCs) are unable to inhibit EndMT in the mitral 
VECs. We used conditioned media from the ECFCs in the EndMT experiment in the 
mitral VECs and observed no effect on EndMT (see Figure 7.8). This confirms that 
inhibition of EndMT may be specific to interstitial and mesenchymal cells. 
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Figure 7.8. Western blot analysis of aSMA expression in mitral VECs grown in normal media for 6 days 
(lane 1), treated with ECFC conditioned media (lane 2), treated with TGF~ (lane 3), and treated with TGF~ 
and ECFC conditioned media (lane 4) Densitometric quantification of aSMA expression normalized to 
~Actin is displayed graphically. 
Discussion: 
We identified endothelial and mesenchymal cell types that can induce quiescent 
and normal valvular cell phenotypes. Such cells could, in future studies, be applied to 
TEHV constructs and analyzed first in vitro (after bio-reactor conditioning) and then in 
vivo. We speculate that a proper equilibrium between the interstitial cells and overlying 
endothelial cells at the onset of the TEHV construct will initiate cellular communications 
and interactions that will be permissive for TEHV development and function. 
Furthermore, we propose that the cell-cell interactions will be responsive to cues 
delivered by bio-reactor conditioning and subsequently to in vivo hemodynamics, to 
ultimately produce a TEHV with high and long term function. 
Our results from this study are limited in that we screened only one candidate 
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interstitial cell. Our second candidate mesenchymal cell was amniotic fluid 
mesenchymal cells (AF-MSCs) but these cells were not available for this study. AF-
MSCs are of high interest because they have shown great promise for use in tissue 
engineering applications due to their ease of accessibility and multilineage differentiation 
potential. Additionally, a colleague at Boston Children's Hospital, Dr. Dario Fauza has 
extensive expertise with ovine fetal stem cell [217]. While this may be a weakness of our 
current study, we believe that the critical component ofthe TEHV is not necessarily the 
source of the mesenchymal cell per se, but the interaction that will occur between the 
endothelial and mesenchymal cells when seeded on a valvular construct and implanted in 
vivo into the pulmonary valve position. Our preliminary evidence suggests that perhaps 
BM-MSCs have this capability. 
Our approach has additional limitations because we are comparing the effect of 
candidate cells on native valve cells, an interaction that will not occur in a TEHV. We 
must test the interaction of the candidate endothelial and interstitial cells to determine if 
they regulate one another the same way they regulate the valve cells. The challenge of 
this experiment is that we have only observed weak EndMT in the ECFCs, (and not in the 
CAECs), therefore we cannot testthe inhibition ofEndMT by candidate interstitial cells. 
While this may be a drawback of our system, we currently do not have access to any 
other endothelial candidate cells with this EndMT capability. Regardless, we believe the 
more relevant issue for the TEHV is not whether EndMT is inhibited, but whether the 
endothelium can maintain a quiescent and healthy interstitium, which we hope to attain 
with our candidate cell sources. 
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Chapter 8. Investigating valve cell dynamics in TEHV explanted after 3-6 weeks in 
vivo 
One of the main goals in the Mayer lab is to produce a tissue-engineered heart 
valve (TEHV) that can outperform those previously designed and tested in the lab. The 
previous in vivo work from our lab involved seeding cells on to a biomaterial designed to 
mimic the PV. The cells were selected to produce a construct with sufficient integrity to 
provide suture retention and prevent leakage. The Mayer lab has recently assessed the in 
vivo performance of a novel material called polycarbonate urethane urea (PCUU) [218, 
219], which was implanted without cells or ECM in the pulmonary outflow tract of 
sheep. This biocompatible scaffold material has desirable biomechanical properties and 
was electrospun into elastomeric sheets ofthickness ranging from 120-180 !liD, and 
implanted via cardiopulmonary bypass into the native anterior pulmonary leaflet position. 
The valve function was evaluated by epicardial echocardiography at the time of implant 
and just prior to explant at weeks 1, 3, 6, and 16. The leaflets demonstrated adequate 
function with zero to mild regurgitation. At explant these valves were assessed for 
mechanical properties, histology, and immunohistochemical staining. Histology revealed 
persistence of scaffold material up to 16 weeks with cellular infiltration throughout the 
leaflet. A section of three of these leaflet samples was used for cellular isolation to 
determine the identity of the cells that had populated the PCUU scaffold. From these 
leaflets, two distinct cell populations were isolated (see materials and methods) and the 
examined with a variety of methods to assess phenotype. This represents the first time 
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that cells have been retrieved and analyzed from an implanted TEHV and/or from this 
novel bioreactor. An important question we are addressing is whether or not the PCUU is 
permissive for VEC and VIC viability and function. 
Cell Isolation: 
TEHV explanted at 6 weeks (n=2) and 4 months (n=l) were enzymatically 
digested with collagenase to release cells from the PCUU construct as single cell 
suspension. The cells were cultured on gelatin/FN -coated dishes in VEC growth medium 
until colonies arose. These colonies were distinguished as endothelial or interstitial via 
staining with the Griffonia simplicifolia isolectin B4 (IB4), a carbohydrate binding 
protein that binds to the terminal a-galactosyl residues expressed by non-primate 
endothelial cells, and has been shown to bind valve endothelial cells [220, 221]. Figure 
8.1a illustrates this process in a schematic form starting from the tissue explant to the 
colony separation. Figure 8.1 b includes representative images of these colonies, with the 
teECs on the top, and the te VICs on the bottom. These colonies were distinguished as 
endothelial or mesenchymal via their ability or inability, respectively, to uptake isolectin 
B4, as shown with staining in Figure 8.1 b. This staining was verified by flow cytometry, 
as shown in Figure 8.1 c, where the teECs stain positively for isolectin B4 but the te VICs 
do not. This demonstrates that we have isolated distinct endothelial and mesenchymal 
populations, which we will now refer to as teECs and teVICs, respectively. We obtained 
a total ofthree samples, TE-l (6 week animal), TE-2 (6 week animal) and TE-3 (4 month 
animal). In addition to the tissue engineered samples we also obtained native valve 
endothelial and interstitial valve cells from the pulmonary valve (labeled pvEC and 
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pvVIC respectively) for comparison. Peripheral blood endothelial colony forming cells 
(pbECFCs) were analyzed in parallel as a non-valvular EC. 
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Figure 8.1. 1a: Cell Isolation procedure with enzymatic digestion and subsequent colony separation. 
Endothelial and interstitial cells were distinguished using the marker IB4 isolectin, which is endothelial cell 
specific. Phase contrast and immunofluorescence staining with IB4 lsolectin is shown in 1 b, and this 
staining is confirmed with flow cytometry in 1 c. 
Endothelial Cell Characterization 
The teECs were analyzed with a panel of phenotypic and functional endothelial 
cell markers to determine how they compared to the native pulmonary valve endothelial 
cells. In Figure 8.2a both cell populations displayed characteristic cobblestone 
morphology, and bound IB4 Isolectin, and expressed VE-Cadherin, but not aSMA. The 
western blot in panel 8.2b confirms this expression of CD31 and VE-cadherin, but not 
aSMA. Additionally, these cells possessed the scavenger pathway for metabolizing 
acetylated-low density lipoprotein, indicated in their ability to endocytose acetylated 
LDL, a function associated with endothelial cells [134]. 
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Figure 8.2. Phenotypic characterization of tissue engineered endothelial cells as compared to pulmonary 
valve endothelial cells. In Figure 2b both teEC and pvECs display cobblestone morphology, bind IB4 
isolectin, uptake acetylated LDL, stain positively for VE-Caderin and negatively for aSMA. The expression 
of the markers CD31 , VE-Cadherin and the absence of aSMA expression is confirmed in the western blot 
data in 2b. 
In terms of endothelial cell function, we used two different assays, the tube 
formation assay and leukocyte adhesion assay. In Figure 8.3 , both the teECs and the 
pvECs were able to form tubes of similar length when cultured on a Matrigel2-D surface. 
This is a widely used assay to assess the morphogenic ability ofEC. Additionally, when 
both cells were treated with TNFa, they were able to upregulate the adhesion molecules 
E-selectin, ICAM-1 and VCAM and then bind human leukocytes, which is a critical 
property of endothelial cells. [51] 
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Figure 8.3. Functional Characterization of endothelial cells. In 3a both cells demonstrate the ability to form 
tubes of similar length when grown on matrigel. In 3b. a representative image illustrates the binding of 
leukocytes to TNFa stimulated teECs cells, the quantification of which is shown in the bar graph on the 
right. 
Interstitial cell characterization 
The interstitial cells were also tested with a panel of phenotypic and functional 
markers to compare with the native pulmonary VICs. In phase contrast (Figure 8.4A) 
both cells types exhibit a spindle shaped, fibroblast like morphology, and are positive for 
the markers aSMA, vimentin [61, 71], and decorin [72, 222], which we have used to 
characterize VICs in previous sections. (In the vimentin panel, the green staining is f-
Actin, and the red staining represents the vimentin staining). The teVICs and the pvVICs 
did not express VE-Cadherin and did not take up acetylated LDL, demonstrating that the 
VICs are distinct from the VECs. The expression of aSMA and the lack of both CD31 
and VE-Cadherin staining are confirmed in the western blot in Figure 8.5a. 
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Figure 8.4. Phenotypic characterization of tissue engineered interstitial cells and pulmonary valve 
interstitial cells. By phase contrast imaging both teVICs and pvVICs display a mesenchymal morphology, 
stain positively for aSMA, vimentin, and decorin, but negatively for VE-Caderin. Both cell types fail to 
uptake acetylated LDL, confurned by the lack of staining in the far right images. 
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Figure 8.5. Sa. Western blot confirming expression of mesenchymal marker aSMA and lack of endothelial 
markers CD31 and VE-Cadherin in both pvVICs and teVICs as compared to the pvECs and teECs. Figure 
5b shows the activation aSMA expression) of valve interstitial cells with the addition of TGF~ and heparin, 
but not with the addition ofVEGF. aSMA expression of the activated pvVICs and teVICs is quantified as 
the number of aSMA positive cells per 1000 nuclei in the corresponding bar graph. 
We also used a number of functional assays to further characterize these 
interstitial cells. The first involved the response of VICs to a variety of chemical stimuli. 
Certain vasoactive agents, such as histamine have been shown to increase contraction and 
136 
activation of the VICs [60, 75]. TGF~ has also been shown to be a potent stimulator of 
the VICs from a quiescent to activated phenotype. Therefore, we tested cell response to a 
panel of stimuli and determined their effects on cell activation as assessed via aSMA 
expression. In Figure 8.5B, the results from this activation assay are shown both 
graphically and with representative images ofthe teVIC-1 cells. As is evident from the 
graph, both the teVIC-1 and the native VIC had very similar responses to these stimuli, 
and upregulated aSMA expression in response to TGF~ and heparin, but downregulated 
aSMA in response to VEGF. An additional functional assay that is closely connected to 
activation is cell contractile activity, which we assessed using our free floating collagen 
gel assay we introduced in Chapter 3. In this assay we compared all three teVIC 
populations with our positive control (pvVIC), and negative controls (ECFC and no cell). 
While we did observe a variation in teVIC contraction, it was always significantly more 
contractile than the negative controls (Figure 8.6a) .. 
The final functional assay we performed was to probe the multilineage 
differentiation potential of these mesenchymal cells (Figure 8.6b), a property that has 
previously been established in the literature [70]. While it has been established that the 
VECs have osteogenic differentiation potential, only recently have the VICs been studied 
for their osteogenic potential, and this it is a much less widely used assay for 
characterization ofVICs. Both teVICs and pvVICs were cultured in osteogenic media for 
three weeks, at which point cell monolayers were stained with a Von Kossa stain, which 
detects the presence of calcium salts. The staining in Figure 8.6b confirms positive 
staining in both the teVICs and the pvVICS. 
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Figure 8.6. Functional characterization of interstitial cells. 6a describes the contraction of pvVICs, and the 
three teVIC cells in the free floating collagen gel contraction assay at 8hrs, indicating contractile activity of 
all cell types . 6b. demonstrates that both teVICs and pvVICS have osteogenic differentiation capability by 
the positive von Kossa staining in the osteogenic assay. 
EndMT in the teEC 
On. a phenotypic level, the teECs and teVICs appear to be very similar to the 
native VECs and VICs, but we wanted to investigate further, to assess their similarity on 
a functional level. One specific functional characteristic of VECs is their unique ability to 
undergo EndMT, which has been demonstrated (in our lab and others) to occur in aortic, 
pulmonary, and mitral valve cells of both sheep and human origin [50-52]. This process 
of EndMT is critical during development of the valve cells, but may also play a role in 
the remodeling of the adult valves, and it is an inherent ability that has not been observed 
very frequently in other non-valvular endothelial cells. 
We performed the standard EndMT assay by treating the cells with TGF[3 for 8 
days and then used several methods to assess transdifferentiation of the cells. Figure 8.7 
shows the alteration in cell morphology in the teECs that results from TGFP treatment, as 
well as the induction of a SMA with concurrent loss of VE-Cadherin expression in 
immunofluorescence staining. These results were confirmed in a large western blot 
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EndMT panel (Figure 8.8), which included teECs from all the 6-week and the 4-month 
timepoints, as well as the native pvECs (our positive control), and our negative control, 
pbECFCs, which do not undergo EndMT. The three different teEC samples showed a 
range of responses to TGF~ treatment, with TE-l displaying spontaneous EndMT, TE-2 
showing slight aSMA expression that was unaffected by TGF~, and TE-3 with a robust 
EndMT response. This is in comparison to the robust EndMT in the native pvECs, and 
the lack ofEndMT in the negative control (pbECFC). To confirm these western blot 
results, RNA from the same samples was isolated and tested for the expression levels of 
the EndMT markers Snail, Slug and MMP2 (Figure 8.9). The results from all three TE 
populations were averaged to produce the standard deviation show in the graph, and 
confirm that the EndMT markers increase with TGF~ stimulation in the teECs and the 
pvECs, but not in the pbECFCs. 
These results confirm EndMT, but we also sought to confirm this 
transdifferentiation at a functional level, by using a leukocyte adhesion assay. As 
previously mentioned a leukocyte adhesion assay tests the ability of cells to upregulate 
the surface molecules I-CAM, V-CAM and E-selectin in response to TNFa, which is a 
specific capability of endothelial cells. We tested teEC-1 and pvEC that had been treated 
with and without TGF~ in this assay, and confirmed the differentiation of both cells to a 
mesenchymal cell type via the loss in ability to bind HL60 cells (a human leukocyte cell) 
(Figure 8.1 0). 
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Figure 8.7. TGFB mediated EndMT assay on teECs is confirmed via the change in morphology in phase 
contrast (on left), the loss ofVE-Cadherin expression (middle panel), and the increase in aSMA expression 
on the teECs (images on right). 
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Figure 8.8. EndMT assay on three teEC populations, pvECs, and pbECFCs. The three teECs are shown on 
the left (TE-l , TE-2, and TE-3), with varying EndMT capability, the pvECs demonstrate a robust EndMT 
(as indicated by robust aSMA expression), and the pbECFCs do not undergo EndMT in this experiment. 
Densitometric quantification of CD31 , VE-Cadherin, and aSMA expression normalized to ~Actin is 
displayed graphically. 
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Figure 8.9. RT-PCR for EndMT markers on teECs, pvECs and pbECFCs. Both the teECs and the pvECs 
upregulate the three EndMT markers, Snail, Slug and MMP2, while the pbECFCs display no change in 
expression. In this graph the average of all three TE samples is displayed. 
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Figure 8.10. HL60 binding assay on teECs treated with TGF~ for 6 days confirms the loss of endothelial 
phenotype. The representative images indicate that teECs treated with TGF~ lose the endothelial ability to 
bind leukocytes when treated with TNFa. Quantification of the number ofleukocytes adhered per mm2 is 
displayed graphically. 
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The range in EndMT response of these three teEC populations may be attributed 
to the same heterogeneity that has been observed in the native VEC population. To 
confirm the presence of multiple subtypes, clonal subpopulations from one of these 
samples (teEC-1) were isolated and tested for EndMT capability, and six representative 
clones are shown in Figure 8.11. Clone B4, B10, and D12 all display a robust EndMT 
response in the induction of a SMA and downregulation of their endothelial markers 
CD31 and VE-Cadherin, whereas the clones F3, G4 and H11 express minimal differences 
in their levels of aSMA, indicating unresponsiveness to TGF~ stimulation. Interestingly, 
clone F3 , while it does not show increased a SMA expression, does have a striking loss of 
both CD31 and VE-Cadherin, which is very unusual compared to any other clone we 
have encountered. These results for each clone were confirmed with RT-PCR for the 
EndMT markers slug and MMP2. As Figure 8.12 demonstrates, many of these clones 
display an upregulation of the EndMT markers Slug and MMP2 when stimulated with 
TGF~. 
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Figure 8.11. EndMT assay on six clones isolated from TE-l (6week) sample. Clones B4, B 10, and D 12 
display a robust EndMT phenotype by the upregulation of aSMA, whereas the remaining clones are either 
unresponsive (F3 and G4), or display a weak EndMT. Densitometric quantification ofCD31, VE-Cadherin, 
and aSMA expression normalized to ~Actin is displayed graphically. 
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Figure 8.12. EndMT Markers in teEC clones. Quantitative real time PCR analysis of the EndMT markers 
Slug and snail for the teEC clones treated with TGF~ (normalized to ~Actin expression). The clones B4, 
BlO, Dl2 and F3 indicate some upregulation of the EndMT markers. 
Conclusions/Discussion 
Previous in vivo studies of tissue engineered heart valves from the Mayer lab 
have tested different materials seeded with a range cell types. Conventional analysis of 
these valves involves functional evaluation in vivo via echocardiography, and 
examination of the explant for cell infiltration, matrix deposition, and leaflet mechanical 
properties. While immunohistochemistry may be employed to stain for specific cellular 
markers in the tissue (i.e. , CD31, aSMA, etc), there is no record ofthese cells being 
removed from the tissue and examined for further analysis. Our study shows that the 
scaffold is permissive for cell infiltration and survival, as cells with proper VIC and VEC 
function have populated the scaffold 
These results show that this elastomeric scaffold is permissive for VEC and VIC 
infiltration and survival, and that the cells populating the scaffold mimic the native 
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pulmonary valve cell phenotype and function. Regardless from where these cells arose, 
this data suggest that inherent properties of the valve location and scaffold design allow 
for repopulation of the ' right' cells in the 'right' location. 
An important observation from this study is the heterogeneity of the EndMT 
response in the valve cells from the different time points. We were somewhat limited in 
the availability of tissue from these explants, and thus were only able to obtain three 
samples: two six week time points and on 4 month time point. It is notable that both of 
the six week time points (TE-l and TE-2) displayed differential responses to TGF~ 
(spontaneous EndMT vs. unresponsive EndMT) via western blot, but these variations 
may be due to the heterogeneity of the cell population, which was proven via clonal 
analysis ofEndMT. While apparent differences in the EndMT capability of these cells 
may be linked to the stages of remodeling in the leaflet itself, and therefore implant 
timepoint, the important observation is that these cells still retain the ability to undergo 
EndMT, despite their lifespan in vivo. 
An important question to address in regards to these cells is their location of 
origin. A limitation of this study is that it is impossible to determine true cell source 
without further in vivo studies, but we may speculate on two potential cell sources. One 
is that these leaflets were repopulated by cells that had migrated from the surrounding 
tissue, possibly from the valve annulus. One technique to address this hypothesis would 
be to apply an immunofluorescent marker to the incision site at the annulus of the valve 
before implantation of the leaflet, to label the cells populating the junction between tissue 
and scaffold. A second potential source of these cells could be the adherence of cells 
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from the bloodstream to the scaffold surface, followed by transdifferentiation and 
migration into the scaffold. These circulating endothelial progenitor cells may have the 
capability of undergoing EndMT and repopulating the valve with proper stimulus once 
they have adhered to the leaflet. To confirm this hypothesis, it would be necessary to 
label these circulating endothelial cells. 
Despite these limitations and the uncertainty of cell origin, these results have 
important implications for the field of tissue engineering because they represent the first 
observation of proper seeding of an acellular scaffold with cells possessing the functional 
characteristics of native valve cells. 
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Chapter 9: Discussion/Conclusions 
In this thesis we explored the cell dynamics of the heart valve as related to natural 
homeostasis, disease progression, and tissue engineering. Using an in vitro co-culture 
model we revealed a novel two-way communication between mitral valve endothelial and 
interstitial cells. We propose that this communication promotes a healthy valve 
phenotype and function by inhibiting EndMT and suppressing VIC activation (Figure 
9.1). We made a similar observation in the aortic valve, where VEC-VIC communication 
may prevent the process of an EndMT mediated osteogenesis. We have also used the 
VEC-VIC co-culture model to identify possible candidate cell sources for a tissue 
engineered heart valve. And finally, we show that cells that populated a tissue engineered 
pulmonary valve leaflet, created using an acellular scaffold, are phenotypically and 
functionally similar to native valve cells. 
Suppress 
a SMA 
VEC 
VIC 
Prevent 
EndMT 
Figure 9 .1. Cellular interactions that promote homeostasis in the heart valve 
We originally hypothesized that a dynamic and reciprocal interaction exists 
between valvular endothelial and interstitial cells to maintain homeostasis in the heart 
valve, and that this homeostasis is disrupted in diseased states. This dynamic and 
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reciprocal interaction would be crucial to the success of a tissue engineered heart valve 
for it to grow with the child. Our results indicate that the VICs can prevent TGF~ 
mediated EndMT in the VECs and conversely that the VECs can promote a quiescent 
phenotype in the VICs (see Figure 9.1 above). While we have elucidated the dynamics at 
a cellular level, we have yet to identify the precise soluble factors mediating these 
interactions. We tested a number of potential factors that may be present in the VIC 
conditioned media (VEGF, HB-EGF), but obtained negative results. Future studies are 
still needed to identify the soluble mediators at a biochemical level. Identification and 
verification ofthese active factor(s) could provide potential therapeutic targets for valve 
disease. 
We have studied the relevance of these cell-cell dynamics in the context of 
disease, specifically calcific aortic valve disease. We created a model of calcific aortic 
valve disease in which VEC or VECs were induced to undergo calcification. Our model 
is one of the first to address these considerations of cell-cell interactions in the context of 
CAVD, and for the first time, we have identified a possible connection between EndMT 
and CA VD. Our results suggest that the process of EndMT may be a precursor to 
calcification in the aortic VECs, and therefore inhibition of EndMT may also inhibit 
calcification. Further studies to identify the active component secreted by the valve 
interstitial cells could provide a critical tool for preventing EndMT and/or CA VD. 
Our model of CA VD attempts to capture the important cell dynamics in natural 
homeostasis, and may be useful for future studies. While our 2D indirect co-culture 
model (see Figure 4.2) does not incorporate the dynamic, 3D components of the native 
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valve environment, we believe it offers a unique perspective for studying valve cell 
interactions and potentially an ideal platfonn for screening of drugs to prevent or treat 
CAVD. We also presented a 3D model (refer to Figure 5.10) for studying EndMT which 
may be further developed to incorporate more sophisticated cell-cell dynamic studies by 
inclusion of both cell types within the 3-D hydrogel. Labeling one ofthese cell types 
could provide insight into the connection between CA VD and EndMT, specifically which 
cell type may play a dominant role in the calcification process in a 3-D environment. 
Our fmdings of reciprocal cell-cellmteractions can be extrapolated to the field of 
tissue engineering by highlighting the importance of recapitulating a healthy valve 
phenotype in a TEHV leaflet. As demonstrated in recent work by Hoerstrup and others 
[223, 224], the field of tissue engineering is evolving towards a sophisticated state where 
diagnostics and technology allow for early detection of cardiac abnormalities, and 
replacement and repair procedures may soon be performed in utero. These advances in 
the field have brought about the identification of novel cell sources that may prolong the 
functional life ofthe TEHV, currently limited to 20 weeks in vivo. We have tested a 
selection of these cell sources and show that they interact favorably with native valve 
cells, which suggest these cells may be able to function as VEC or VIC in a tissue 
engineered construct. These studies help to address the persistent question in tissue 
engineering of cell source selection, which we now know is very important in promoting 
and maintaining homeostasis in the valve. 
This study has also explored the result of placing an acellular tissue engineered 
material in vivo. We have observed that the body has the remarkable capability of 
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populating the acellular pulmonary valve leaflet within weeks after implantation with 
cells of the seemingly correct phenotype. This finding has important implications for the 
field of tissue engineering, as it SlJggests that pre-seeding tissue engineered constructs 
may be less critical than we previously believed. Next steps would include identifying the 
origin of these cells. To determine ifthe cells were derived from the surrounding valve 
tissue, an option would be in vivo labeling of the surrounding tissue prior to leaflet 
implantation with a GFP-adenovirus. Conversely, if these cells were derived from 
circulating progenitor cells, such as ECFCs, we could consider isolating and labeling an 
autologous population of ECFCs, which could then be infused by IV into the animal. 
An additional consideration is that if these cells did derive from a circulating 
population, what factors caused them to differentiate into VEC and VIC? This raises the 
question of how hemodynamics and mechanical forces (shear stress) influence cell 
differentiation and phenotype. To address this question it would be critical to introduce 
flow into our static in vitro system, to determine how cell-cell interactions are affected in 
a dynamic environment. Translating this concept to the in vivo level, we hypothesize that 
the same biomaterial implanted into the pulmonary artery would attract cells and become 
populated but that these cells would be large vessel EC (with no capacity for EMT, as we 
have previously demonstrated with the carotid artery EC) and smooth muscle cells. This 
would suggest that the unique hemodynamic environment of the pulmonary valve 
promotes the differentiation to VEC and VIC phenotypes. 
A final study utilizing this tissue-engineering model would be to determine what 
effect these cells have on one another in vitro. For these cells to embody the true valve 
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cell phenotype, they should have the capacity to regulate one another in vitro (i.e. inhibit 
EndMT in the teECs and suppress SMA in the teVICs),just as we have observed in our 
native valve cell populations (See Chapters 4, 6). Further studies to confirm these 
interactions could verify that these cells recapitulate a true valve phenotype. 
Limitations/Considerations 
Our studies provide important insight into the cell biology of the mitral, aortic, and 
pulmonary valves. There are, however, several limitations. The first is that subtle 
differences may exist with respect to orientation of the cells within the valve. Research 
has proposed that ventricular versus atrial endothelium possess different properties with 
regards to gene expression and protein secretion [225, 226]. Additionally, certain regions 
of the aortic valve are more prone to calcification than others, which may be a function of 
hemodynamics, or possibly a result of cell heterogeneity [160-162]. We do not know 
which side .of the valve the VEC clones are derived from. While this may confer specific 
properties upon our clonal populations, we believe that these cells have the ability to 
adapt to specific environments, and therefore, once they are seeded onto scaffolds and 
exposed to pulsatile flow in our bioreactor, they will adapt accordingly. 
Another potential concern is that all of these studies have been conducted in sheep 
and it is unclear how well this model will be transferable to humans. If this project is 
successful, human VECs and VICs must also be analyzed. It is fortunate that in the 
Bischoff lab we have human VICs and VECS collected from heart transplant recipients 
(under approved IRB protocols). These cells can be tested to confirm key results obtained 
from ovine cells. 
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Despite these potential limitations, we hope that this research will contribute to 
the field of tissue engineering and heart valve disease by highlighting the importance of 
cell-cell interactions in maintaining homeostasis in the valve. The field of heart valve 
research is driven by the increasing number of adults with heart valve disease and the 
number of children born each year with congenital heart defects. Both of these 
·populations require better treatments and or heart valve replacements. In the setting of 
disease we hope that our work can be used to better understand, treat, and ultimately 
prevent CA VD. In the field of tissue engineering, we hope that our work has highlighted 
the importance of a two-cell system for maintaining valve homeostasis to ultimately build 
a tissue-engineered valve than can be successfully implemented in the clinic. 
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